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1. Introduction
Opioids for chronic pain management have become increasingly controversial, yet many
patients continue to be treated with high doses for prolonged periods of time. The miscon‐
ception between patients and providers alike is that these drugs can be taken without conse‐
quences. This liberalized thinking is far from the clinical practice of just two decades ago.
Opioids have been destigmatized, and the origins can be traced to industry and a few thought
leaders that have since retracted their belief that opioids may be prescribed without negative
consequences.
During the 1990's chronic and cancer pain was recognized as being undertreated worldwide.
The result was to soften prescribing resistance, particularly in the United States. As a result,
many states in the U.S. passed intractable pain treatment acts to protect physicians from
disciplinary action when prescribing opioids for non-cancer pain, as well as cancer pain.
Unfortunately, that liberalization of opioid prescribing has been associated with a parallel
increase in prescription opioid overdoses and deaths. Over the past decade, opioid overdose
risk has become such a serious risk factor that Naloxone rescue units have been developed for
home use. This rampant failing of safe prescribing habitry has resulted in a ready supply of
opioids and a willingness of the consumer to seek these drugs.
Healthy Americans issued a report in October 2013 stating:
"Drug overdose deaths exceed motor vehicle-related deaths in 29 states and Washington DC.
Misuse and abuse of prescription drugs costs the country an estimated $ 53.4 billion a year in
lost productivity, medical costs and criminal justice costs, and currently only one in 10
Americans with a substance abuse disorder receive treatment." [1] Clearly, the indiscriminate
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use of opioids has overwhelmed practical and safe prescribing methods, and regulatory
agencies have been slow to respond to this opioid prescription epidemic.
This chapter will review recent studies on the subject of opioid prescribing, misuse, and abuse,
and present arguments both for and against opioid therapy for chronic pain. Prescribing
providers are encouraged to evaluate patients for risk factors of opioid abuse prior to initiating
opioid therapy and during treatment. This is good medical practice. Additionally, it is stressed
to prescribers to limit opioid doses and duration of drug exposure to further decrease the
potential for adverse outcome. [2] Therefore, it is important to educate providers and patients
about alternatives to opioids, including non-pharmacologic treatment, and introduce this
multimodality concept.
Pain is subjective, and must be addressed from the patients' point of view. Most physicians
struggle with pain as a diagnosis because there are few tools available to verify its existence.
The value of advanced therapies, such as diagnostic interventions, help characterize the
diagnosis, and opioids are rarely a first treatment step in the clinical treatment of chronic pain.
Medical specialists are encouraged to improve sharing information about analgesic modalities
and alternative interventions that may help an individual patient limit their opioid dose.
Advanced therapies, such as interventional options, may not be known to midlevel providers
who care for many patients with chronic conditions. Exhausting conservative measures to
reduce the opioid load is necessary to optimize best clinical outcome and reduce risk in a
clinical pain practice.
Opioid prescribing became an easy and time efficient method to treat pain in non-pallia‐
tive  care  settings  over  the  past  two  decades.  The  Federation  of  State  Medical  Boards
endorsed  opioids  as  a  legitimate  treatment  option.  [3]  Like  any  clinical  therapy,  some
patients seem to do very well with chronic opioid therapy while others do not. The overdose
and diversion problems associated with increased opioid prescribing have recently called
for enhanced regulatory activity from a public health perspective. Rethinking prescribing
habits is different than relating new therapies in the traditional care model.  Opioids are
expected  by  patients,  and  as  a  society,  expectations  of  relief  are  considered  a  “right”,
resistance to change is met with varying degrees of resistance. These layers of complexity
in the clinical setting place the burden on the provider to secure a course of care that is
compassionate, yet safe and effective.
Over the past 20 years, the prevalence of chronic pain and selecting the proper treatment
has  remained  a  consistent  challenge  for  providers  and  patients  alike.  Advances  in  the
treatment of chronic pain have primarily centered on pharmacologic management, therapy,
and  interventional  tools.  Positive  outcomes  are  often  associated  with  a  multimodality
approach, but the financial challenges of the healthcare system may limit access to these
sophisticated treatment options. Long considered a fifth pathway, proper treatment of pain
is necessary,  but will  be unlikely to support a priority position in the healthcare hierar‐
chy of  the  future.  With the  emergence of  innovative  healthcare  payment  programs and
strong government influence, priority will be given to chronic life-threatening disease states,
and followed by those with progressive disabling afflictions. Chronic pain, which is often
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a cruel and disabling state, is not a life-threatening entity. In this rapidly evolving health‐
care delivery system, the pain care provider will  be challenged to render effective care,
increase the quality of life of those in pain, and minimize risk and cost. Not surprisingly,
it is expected that with rising healthcare costs, opioid use will be considered cheap, and a
first choice. Escalating opioid use, however, has a direct relationship with adverse conse‐
quences.  The rapidly increasing supply of  opioids in the United States  underscores this
observation.
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uitics2, 3
5.759
(2.6%)
9,220
(4.2%)
8,761
(3.9%)
11,102
(4.9%)
14,795
(6.3%)
15,163
(6.4%)
14,849
(6.2%)
15,346
(6.3%)
16,482
(6.7%)
16,280
(6.6%)
15,166
(6.1%)
16,006
(6.4%)
16,031
(6.3%) 178%
Pain Relievers -- 6,582(3.0%)
6,466
(2.9%)
8,353
(3.7%)
10,992
(4.7%)
11,671
(4.9%)
11,256
(4.7%)
11,815
(4.9%)
12,649
(5.1%)
12,466
(5.0%)
11,885
(4.8%)
12,405
(4.9%)
12,213
(4.8%)
85%
From
1999
OxyContin® -- -- -- -- -- -- 1,213(0.5%)
1,226
(0.5%)
1,323
(0.5%)
1,422
(0.6%)
1,459
(0.6%)
1,677
(0.7%)
1,869
(0.7%)
54%
From
2004
Tranquilizers 1,940(0.9%)
2,728
(1.2%)
2,731
(1.2%)
3,673
(1.6%)
4,849
(2.1%)
5,051
(2.1%)
5,068
(2.1%)
5,249
(2.2%)
5,058
(2.1%)
5,282
(2.1%)
5,103
(2.0%)
5,460
(2.2%)
5,581
(2.2%) 188%
Stimulants3 1,489(0.7%)
2,291
(1.0%)
2,112
(0.9%)
2,486
(1.1%)
3,380
(1.4%)
3,031
(1.3%)
3,254
(1.4%)
3,088
(1.3%)
3,791
(1.5%)
2,998
(1.2%)
2,639
(1.1%)
3,060
(1.2%)
2,887
(1.1%) 94%
Sedatives 522(0.2%)
631
(0.3%)
611
(0.3%)
806
(0.4%)
981b
(0.4%b)
831
(0.3%)
737
(0.3%)
750
(0.3%)
926
(0.4%)
864
(0.3%)
621
(0.2%)
811
(0.3%)
907
(0.4%) 56%
Marijuana and
Hashish
18,710
(8.6%)
19,102
(8.6%)
18,589
(8.3%)
21,086
(9.3%)
25,755
(11.0%)
25,231
(10.6%)
25,451
(10.6%)
25,375
(10.4%)
25,378
(10.3%)
25,085
(10.1%)
25,768
(10.3%)
28,521
(11.3%)
29,206
(11.5%) 56%
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Cocaine 3,811(1.7%)
3,742
(1.7%)
3,328
(1.5%)
4,186
(1.9%)
5,902
(2.5%)
5,908
(2.5%)
5,658
(2.4%)
5,523
(2.3%
6,069
(2.5%)
5,738
(2.3%)
5,255
(2.1%)
4,797
(1.9%)
4,449
(1.8%) 17%
TOTAL ILLICIT
DRUGS1
23,115
(10.6%)
25,402
(11.5%)
24,535
(11.0%)
28,409
(12.6%)
35,132
(14.9%)
34,993
(14.7%)
34,807
(14.5%)
35,041
(14.4%)
35,775
(14.5%)
35,692
(14.4%)
35,525
(14.2%)
37,957
(15.1%)
38,806
(15.3%) 68%
--Not available
Note: 2002 to 2010 data is based on 2010 National Survey on Drug Use and Health Survey Report. a Difference between estimate and
2010 estimate is statistically significant at the 0.05 level. b Difference between estimate and 2010 estimate is statistically significant at the
0.01 level.1 Illicit Drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription-type psycho‐
therapeutics used nonmedically. Illicit drugs other than marijuana include cocaine (including crack), heroin, hallucinogens, inhalants, or
prescription-type psychotherapeutics used non-medically. The estimates for nonmedical use of psychotherapeutics, stimulants, and meth‐
amphetamine incorporated in these summary estimates do not include data from the methamphetamine items added in 2005 and 2006.
2 Nonmedical use of prescription-type psychotherapeutics includes the nonmedical use of pain relievers, tranquilizers, stimulants, or seda‐
tives and does not include over-the counter drugs.
3 Estimates of nonmedical use of psychotherapeutics, stimulants, and methamphetamine in the designated rows include data from meth‐
amphetamine items added in 2005 and 2006 and are not comparable with estimates presented in NSDUH reports prior to the 2007 Na‐
tional Findings report. For the 2002 through 2005 survey years, a Bernoulli stochastic imputation procedure was used to generate
adjusted estimates comparable with estimates for survey years 2006 and later.
Source: Substance Abuse and Mental Health Services Administration. Results from the 2010 National Survey on Drug Use and Health:
Summary of National Findings. http://www.samhsa.gov/data/NSDUH/2k10NSDUH/2k10Results.pdf [170]. Access date 2/22/2012
Table 1. Types of illicit drug use in the past year among persons aged 12 and older: numbers in thousands from 1998
to 2010 (12 years)
There is good evidence that opioids are effective, and the Institute of Medicine (IOM) does
promote pain treatment with these agents, but the rapidly increasing availability of drug does
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seek justification. Opioids in the U.S. are a popular choice to treat painful complaints, with use
rising from 96mg of morphine equivalents per person in 1997 to 710mg per person in 2010.
The staggering opioid availability is equivalent to 7.1kg of opioid for every 10,000 people [4].
This begs the question, is there a proportionate growth in pain and suffering? Have we
undertreated pain as a legitimate affliction for decades, or are we pressured to a more
aggressive care model?
Gram for gram, the U.S. consumes more opioids than any other country in the world. Despite
increasing availability and distribution, limited evidence exists that effective chronic pain
treatment is a reduced cost to society, or improves function. There is an abundance of evidence,
however, that with this increased availability and use, increased morbidity and mortality
escalates in an almost parallel fashion [5].
Unintentional opioid overdoses have exceeded heroin and cocaine deaths combined. Opioids
contribute to 1 death every 36 minutes [6-10]. The societal impact is more complex than most
providers realize. For every death, 9 patients are admitted for substance abuse treatment and
161 for abuse and dependence, with an estimated cost burden of $20 billion [11]. Heroin has
recently reemerged in certain areas of the country, presumably as opioid availability decreases.
Novel combinations of fentanyl and heroin are a fatal combination.
Nonmedical use of opioids for recreational purposes is now considered an epidemic in the
U.S. [12]. The inevitable catastrophe of reckless prescribing and aberrant consumer behavior
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is measured by unexpected adverse consequences. This high risk behavior can result in
disastrous outcomes. For every 50 people who take recreational opioids, the result is an
unexpected death [13]. First observed a decade ago when emergency department visits due to
opioid poisoning rose by almost five-fold, regulatory agencies remained silent. The response
to this crisis has remained feeble. The perception that pain is undertreated, promoted by special
interest groups and pharma, has led to an explosion of prescriptions and supply slowly being
recognized as a major healthcare challenge.
According to the ARCOS data provided by the Drug Enforcement Administration, major
classes of opioids have increased substantially in total grams of distribution despite the readily
available data linking adverse outcome to availability [14]. In the early 1990s opioid analgesics,
led by morphine, Fentanyl, Oxycodone, and Hydrocodone had significant increases in use.
From 2004-2011 Hydrocodone use increased by 73%, morphine 64%, methadone 37%, and
Fentanyl 35%. Sales of opioids quadrupled between 1999 and 2010 [15]. Hydrocodone is the
number one dispensed prescription in the U.S., and the U.S. is the world leader in its con‐
sumption [16]. The most remarkable increase in use and availability was buprenorphine.
Buprenorphine is indicated for the treatment of addiction and dependency, and in some cases,
pain. This is the irony of controlled substance management. To control risk, the provider must
be educated and vigilant in techniques to avoid dependence, misuse, abuse, and diversion.
The flawed concept of dependency and addiction presents itself with buprenorphine. Bupre‐
norphine is a substitute drug of dependency, and not surprisingly, abuse is on the rise.
The Drug Abuse Warning Network (DAWN) exists to provide information to governmental
agencies about emergency department visits related to opioid poisoning. Even codeine, which
is reported to have a decrease in prescriptions this decade, increased in misuse. Hydromor‐
phone led the way with the highest increase between 438%, followed by Oxycodone, Fentanyl,
Hydrocodone, and Methadone. Prescription opioids revealed in DAWN data mention an
increase in adverse events 4% in 1996 data to 20% in 2011 [17]. Not surprisingly, patients
seeking detoxification also increased during this period. With the increasing liberalization of
laws surrounding marijuana, a drug of abuse that should be treated no differently than any
other molecule of abuse and misuse. This drug has also realized an increase in adverse
outcomes. Marijuana is considered a safe and benign drug by a vast majority of Americans,
but like any abusable substance, has risk. Unlike every other drug, the legislation of marijuana
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for medical or recreational purposes was not the doing of the FDA, but by the voter. Marijuana
is a drug of consequences. It is abusable, associated with psychometric impairment and
addiction. Prior to functional executive brain maturation at age 25, irreversible impairment of
IQ may occur. Definable benefits to medical application are being studied. Bone healing,
neuronal protection after stroke, and seizure management may benefit from a medical
application. Smoking the drug to obtain THC is unmeasured and variable. Liquid variants
may be superior. As the THC potency continues to be engineered and enhanced in the weed,
the medical value may be diminished. THC concentration has increased from 2% in the 1970s
to 8% and rising [18]. Interestingly, although highly habituating, patients seeking detoxifica‐
tion from cocaine have decreased.
The use of controlled substances for recreational purposes or diversion was not realized as a
problem to its full extent until 1996. Prior to 1996, the DAWN and ARCOS data did not reveal
any particular trend in abuse, misuse, or diversion. During that same period of time, medical
use of opioids was increasing rapidly, but no particular trend divulged the urgent need for
increased scrutiny of these agents. Most believed that the increased use of opioids was
responsible for improved treatment of chronic pain. The opposite appears to be evident.
Despite mounting evidence that chronic opioid therapy does not improve quality of life, their
use continues to rise [19]. Further underscoring this irony is the persistent lack of evidence
supporting chronic use, and the abundance of evidence that reveals these agents are risky, and
in certain patient populations, dangerous. Efforts at educating the medical community are in
place, but persistent widespread use is continuing to promote misuse, abuse, and diversion.
The group most willing to prescribe controlled substances is also the provider with the least
amount of time to assess risk, and apply principles of adherence monitoring. Primary care
physicians are responsible for the largest population of patients chronically exposed to
controlled substances. It surprises many that the vast majority of opioid prescriptions are from
general practitioners, family medicine, and internists. Anesthesiologists and physical medi‐
cine, traditionally associated with pain clinics, are responsible for only about 6% of total
prescriptions combined [20].
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2. Epidemiology
Epidemiology is the study of factors that determine or influence a pattern in prevalence of
disease or a condition in populations [21]. Healthcare spending accounts for 16% of the gross
domestic product and is continuing to climb, with expectations approaching 25% of the GDP
by 2025 [22]. Chronic illnesses are a major cost driver, with projected increases from 133 million
in mid-2000, to 171 million in 2030 [23]. The healthcare burden of chronic non-malignant pain
is enormous, and a major cost driver in chronic disease. More than ¼ of Americans suffer from
daily pain at a cost of almost $60 billion in lost productivity in the U.S. alone [24]. Those of
lower socioeconomic status experience pain more often. Individuals making $30,000 or less a
year spend nearly 20% of their life in moderate to severe pain. This directly contrasts to
households earning more than $100,000 a year, which experienced pain at 8% of their life or
less. Those that did not finish high school feel twice as much pain as college graduates. A
number of proposed reasons for this discrepancy can be presumed. Those with lower socioe‐
conomic status tend to have more labor-intensive work, and fewer conveniences. The type of
work performed is less ergonomically appealing, and those with lower socioeconomic status
tend to have more drivers of poor well health characteristics, such as tobacco consumption. It
is not surprising that pain medications are a first choice in those suffering from pain, because
they are easily obtainable. Americans spend approximately $2.6 billion in over-the-counter
pain medications alone and $14 billion on analgesics as a class [25].
The burden of pain is also felt psychologically. Over a quarter of patients believe they will
always have pain and there is no solution, and their doctor rarely understands how they feel.
Up to 1/3 of chronic pain patients have reported they received little, if any, relief from
treatments or therapies. The prevalence of pain in the American population is substantial, with
4 out of 10 Americans saying they experience pain daily, which rises in the aging population
approaching 60% in those aged 65 and older. 9 out of 10 Americans say they experience pain
some time each month, which would increase utilization of healthcare services to be directly
related to these incidences of pain. In fact, despite the prevalence of pain, nearly two-thirds
see a doctor only when they cannot stand the pain any longer [26].
Pain remains one of the most frequent chief complaints in the primary care office, with 40% of
primary care visits seeking relief, and 20% of those are chronic pain visits. In primary care
practices, almost 15% of patients require pain medication or treatment. Up to 20% of patients
in a primary care setting are on chronic opioid therapy [27].
Loss of work is a major problem related to pain. Almost 55% of the work force reports having
pain the past 2 weeks and of that, almost 15% experience lost productivity due to pain. One
percent of the work force is absent from work one or more days a week, with headache and
back pain being the most common complaint. Migraines are estimated to affect 30 million a
year, with overall prevalence in the U.S. population approaching 15%. Women are three times
more likely than men to develop migraines, with peak year’s incident age 25-45 [28]. Osteo‐
arthritis, low back, and neck pain is another substantial percentage of the American population
suffering from pain. 16% of the U.S. population, or almost 45 million, report pain directly
related to osteoarthritis [29]. The incidence of low back pain peaks about the sixth decade of
Pain and Treatment82
life, and 50% of Americans report some episode of back pain. Neck pain occurs about half as
often as low back pain, and effects 10% of the general population [30].
3. Anatomy, neurobiology, and nociceptive systems
“The affective motivational aspect of pain originates in the periphery and suffering is not
merely a matter for neocortex, it is profoundly more ancient and primitive biogenetically and
is reflected in fiber tracts and neural networks throughout the nervous system.” [31]
Pain is “an unpleasant sensory or emotional experience associated with actual potential tissue
damage or described in terms as such tissue damage” [32].
Pain is a personal experience, and is a perception of abnormality that relies on descriptors. It
is a sensory event of the peripheral and central nervous system, and is only partially defined
by the initiating or traumatic event. The effects of pain at any level projects changes to the
central nervous system that increase the likelihood of neurobiological changes, within
nociceptive systems. The inciting pain generator becomes less relevant over time, as pain is
promoted neurobiologically. As more recent understanding of these nociceptive systems
evolves, it is better understood that pharmacologic manipulation is often necessary to
modulate chronic pain states.
Acute pain is a symptom of a disease and is usually self-limited. It is provoked by tissue injury,
not just stimulation, and is usually associated with abnormal functioning of somatic structures.
This event could be secondary to emotional responses, autonomic, or a psychological stimu‐
lation and response. It has a biological function to alert and warn the individual, and also
withdraw for healing and resting. Chronic pain however, sometimes can become the disease
itself. It persists beyond the usual course of the acute disease. Chronic pain persists beyond
tissue healing and usually is experienced over three months, or some combination therein,
associated with impaired function and quality of life indices. Like many other chronic
conditions such as hypertension and diabetes, treating chronic pain requires its own set of
paradigms and treatment strategies. If the patient has an uncontrolled pain condition, what
would normally be an eventful recovery could lead to persistent pain, and often requires
chemical therapy or interventions in a multimodality approach to control the pain. Chronic
pain is provoked by a chronic pathological process and can result from a dysfunction in the
central nervous system. The nervous system evolves into a hypervigilant state, or “wind up”,
and in turn activates central nervous system elements that may provoke psychological and
depressive conditions. Autonomic and neuroendocrine responses may be absent, and it is here
that chronic pain is felt to alter biological function [33]. The central nervous system is being
remodified to recognize the neurobiological changes that chronic pain evokes. As many of
these pain pathways are intimately related with the limbic system and primitive brain
structures, associated mood and behavioral changes occur. The interrelationship between the
primitive brain and higher cognitive function eventually signals the prefrontal cortex that an
abnormal sensation is felt. The patient is then motivated to dampen these systems, and when
persistent pain is untreated, impaired restorative sleep capacity is observed, anxiety is
The Evolving Role of Opioid Treatment in Chronic Pain Management
http://dx.doi.org/10.5772/58818
83
detected, and situational depression emerges from these pain states. This further withdraws
the patient from active lifestyle, and other somatic complaints develop as comorbidities.
4. Nociception
A nociceptor is normal if it hurts. The anatomic pathway, spinal thalamic tract, is activated by
a peripheral nociceptor, transmitted to the dorsal horn in the spinal cord, which then pro‐
gresses the signal contralaterally through the spinal thalamic tract to the brain and limbic
structures. The dorsolateral funiculus, a modulating descending pathway, dampens the effect
of pain at the juncture of the first and second order neuron. The second order neuron resides
in a well laminated architecture, the “rexed lamina,” located in the dorsal horn of the spinal
cord. Here it begins, here it is modulated. At the cellular level, opioid receptors at the second
order neuron, which is in the dorsal horn of the spinal cord, diminish the impact of the
nociceptor stimulus.
There are two types of nerves that are relevant to pain processes. Acute pain is a fast, electric-
like pain that is transmitted by A-delta nociceptors. Dull, aching, throbbing, phylogenetically
primitive pain is transmitted by the C-fiber nociceptor. At the cellular level, a process of
transcription and gene induction elaborates algogenic mediators of pain. The algogenic
mediators may be nitric oxide, cholecystokinin (CCK), substance P, and prostanoids, to name
a few. Substance P sensitizes the CNS at the receptor site, where N-methyl-D aspartate
(NMDA) receptors promote activation of ion channels in pain promoting areas.
Pain signaling, from outside in, cutaneous muscle and visceral tissues initiate high threshold
chemical, mechanical, or thermal stimuli to activate neurophysiologic pathways through
electrophysiological activity, and engages the second ordered neuron at the rexed lamina. Both
sodium and calcium influx leads to release of calcium intracellular stores, and decreased
nociceptor thresholds. When this occurs long term, the transcriptive events at the neuron may
become sensitized. This is the beginning of the origination of pain, outside in, toward the spinal
cord. The role of algogenic mediators of pain may lead to a number of descriptive pain states
at this level, such as hyperpathia, hyperalgesia and allodynia. The type 1 and 2 A-delta fibers
are small (1.1 to 5-micrometers in diameter), myelinated, and rapidly conducting (at 5 to 30
meters per second). This is a sharp electric pain. The quick retraction from a hot ember, or
stubbing a toe. C-fibers, are the smaller (.25 to 1.3 micrometer diameter) unmyelinated slow
fibers, (0.5 to 2 meters per second) that give a poor characterization of pain. These are the
“second pain” transmitters that quantify pain poorly. C-fibers are considered polymodal, and
are activated by mechanical, chemical or thermal mechanisms. The vague abdominal discom‐
fort in the viscera is an example of C-fiber mediated pain, leading to vague descriptors of pain
that are poorly localized in the gut. The odd finding that abdominal pain sometimes activates
a discomfort in other parts of the body may be explained by the convergence of afferent activity
at the second order neuron from different structures. Visceral stimulation has often been
observed to incite pain in the shoulder. When adrenergic receptors are activated, peripheral
autonomic dysfunction, and sympathetically driven pain may emerge. Ultimately, these
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sympathetic changes are manifested in pseudomotor changes, and are revealed as the
progressive alterations in the periphery, such as seen in complex regional pain syndrome
(CRPS).
Once converged at the dorsal horn, the A-delta and C-fibers synapse at laminae 1-2, 2A, and
5. At the dorsal horn, a complicated and coordinated activation of many of the important
cascade elements that promote pain occur. Glutamate activation of the AMPA receptor induces
a sodium current and depolarization, with sustained activation of the NMDA receptor.
Proteins and synaptic elements are influenced by brain derived neurotrophic factor (BDNF),
inducing cellular translational events. The cascade of neurogenic inflammation is begun at the
C-fiber with release of substance P, CGRP, and the resultant algogenic mediators of pain. The
A-delta and C-fiber synapse with the wide dynamic range nociceptive fibers and increase the
sensation of pain by a process of “summation” which amplifies pain. With repetitive noxious
input, the WDR neuron is engaged in “wind up” and remain sensitized.
Ultimately, the spinothalamic tract interacts with higher centers directly approximated with
many important nuclei, and deep brain structures. The “personality of pain” is directly affected
by the transmission of brain through these intermediary relationships. Serotonin and norepi‐
nephrine is intimately related to these pathways. Some serotonin receptors seem to be
upregulated with persistent pain stimulation. Dopamine and dopaminergic pathways in the
primitive brain structures are directly affiliated with the emotional and behavioral aspects of
pain. At many points through the periphery to the dorsal root ganglion, rexed lamina, as well
as ascending and descending pathways, opioids have a strong influence on analgesia and the
behavioral aspects of pain. Once pain is interpreted by the higher conscious state, memory and
behavioral influences are introduced. Pain is a global experience, with limbic system engage‐
ment, prefrontal cortex, and primitive brain structures motivating an individual to seek relief.
Of the four types of pain – somatic, visceral, sympathetic, and neuropathic pain – somatic and
visceral are nociceptive pains. Neuropathic and sympathetic are non-nociceptive. The
nociceptive pain from stimulated receptors is normal if it hurts. The non-nociceptive pain rises
from central nervous system and peripheral nervous system dysfunction. There are no pain
receptors in this type of pain, and therefore it is caused by a dysfunctioning nociceptive system.
Somatic pain, or more commonly musculoskeletal pain, is sharp and well localized. The type
of pain that would be termed nociceptive or visceral are opioid responsive. Choosing the type
of medication treatment for different types of pain requires an understanding of the type and
described pain.
5. Scope of problem
The Institute of Medicine has published a report that reveals 116 million Americans suffer from
pain that persists from weeks to years [34, 35]. The estimated financial impact is up to $635
billion per year in the U.S. [36-38]. It would seem logical that treating pain with an opioid
strategy would diminish this staggering number, when in fact there is very little evidence that
the desired relief and productivity is returned with these agents. Contrary to intuition,
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evidence suggests the alarming trend in misuse, abuse, and diversion overwhelms most
potential benefits of chronic opioid use, and might argue against chronic exposure. As
regulatory restrictions relaxed in the 90s, the trend to prescribe opioids increased alarmingly.
Based on the patients self-report of pain, this subjective report is frequently the only tool
provider’s use to initiate treatment deemed chronic in nature. It was erroneously assumed that
the humane approach to addressing a chronic pain condition was to prescribe an ever
increasing load of opioids and adjunctive medication. Evidence is lacking in non-cancer pain
that pain conditions improved as the dose escalated. Opioid-induced hyperalgesia, endocrine
disorders, and the potential for poisoning highlight the better conservative course of care,
supporting a more conservative contemporary decision making. The current trend in chronic
pain care does not seem to reflect this approach.
The National Survey on Drug Use and Health (NSDUH), under the sponsorship of The
Substance Abuse and Mental Health Services Administration (SAMHSA) is distributed to
Americans from age 12 and older. Not surprisingly, marijuana is the most commonly used
substance with 17 million current past month users, followed by pain relieving drugs.
SAMHSA 2012 identified marijuana as the leading drug of abuse in first time users aged 12
and older. Marijuana is considered a gateway drug, and increasingly destigmatized. A
staggering 38 million in 2010 used illicit drugs, which is 15% of the American population.
Nonmedical use of psychotropic therapies from 1998 to 2010 exceeded marijuana, and is ten
times that of cocaine [39].
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The prevalence of those complaining of pain is staggering, estimated to be upwards of 100
million Americans (IOMPPT). Conversely, the incidence of diabetes registers at 25.8 million,
heart disease 16.3 million, cardiovascular accidents 7 million, and all cancers combined at 11.9
million (ADA, AHA, ACA) [40]. With the prevalence of pain affecting roughly 1 in 4 Ameri‐
cans, there is little question why a suffering individual would seek any form of therapy,
including opioids, to treat chronic nonmalignant pain. Most unfamiliar with interventional
pain medicine or other options to treat their pain feel that there is only a pharmacologic
solution. This multimodality approach is often underutilized to reduce opioid use. If it comes
from a doctor, patients believe opioids must be safe. A report by Russell Portanoy and Kathleen
Foley in 1986 opened the door to the subsequent belief that opioids are safe and have little
consequences. The paper titled “Chronic Use of Opioid Analgesics and Nonmalignant Pain:
Report of 38 Cases” opined that opioid maintenance therapy can be a “safe, salutary, and more
humane alternative to options of surgery or no treatment for those patients with intractable
nonmalignant pain and no history of drug abuse” [41]. Further supported by the historical
facts that opioids have been used for thousands of years, and referenced in ancient writings,
the use of opioids found a natural segway into a cost-effective and humane prescriptive
environment. The first steps of an epidemic were born.
All but uncontrolled until the Harrison Act of 1914, there was little regulatory restriction on
narcotics (controlled substances) in the United States. After the occupation of the Philippines
in 1912, and the resultant Hague Treaty, the American response to the concern of British
domination of Chinese opium trade resulted in enhanced law enforcement that had very few
options to curb opioid use and the potential for misuse [42]. The rest of the world was not quick
to adopt or enforce regulation, and until 1961 there were no regulations that addressed world-
wide production and distribution of narcotics. The Controlled Substance Act of 1970 was a
first step to address these concerns when “no relief or cure is possible, or none has been found
after reasonable efforts to legitimize opioid/controlled substances prescriptive purposes.”
Steadily over the past few years, with advocacy and patients’ bill of rights, medical societies
support, and the generation of a perceived fifth pathway of pain control in the community,
opioid use escalated. The National Vital Statistics Office has seen a steady rise in opioid
prescriptions. Available opioids have realized a threefold rise from the late ‘90s. If pain
relievers and tranquilizers were mixed together, as often is the case, the combination would
significantly exceed marijuana use. Cocaine and heroin use remain far behind. This under‐
scores the quadrupled death rate from 1999 to 2010. The patients really haven’t changed that
much, but the exposure to opioids has. [43]
Technology has given us the opportunity to identify and track prescriptive habitry, as well
as patient behaviors. With any sharing of sensitive medical information, controls should be
in place to assure that the proper individuals have access to the data, and HIPAA integri‐
ty is enforced. One of the major questions posed by recent efforts of accumulating patient
data  electronically  is  the  question  of  narcotic  misuse  patterns  by  the  patient,  and  the
potential for inappropriate distribution by pharmacies and physicians. Patient data systems
throughout  the  United  States  address  these  questions  in  different  manners.  Some  em‐
brace the access of law enforcement, others strictly prohibit information exchange to only
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providers, unless the power of the subpoena is in place. Both have pros and cons. Further‐
more, physicians, extenders, dentists, pharmacies and others that prescribe are not required
to  access  this  database.  The  question  of  poor  standard  of  care  is  introduced  when  the
potential for harm exists. An overly relaxed due diligence by the prescriber or dispenser is
to ignore this important technology.
In 2005, George Bush signed into place the National All Scheduled Prescription Electronic
Reporting (NASPER) program which would cross  state  lines  and provide a  database to
reduce  cross  state  seeking and opioid  distribution  activity  [44].  NASPER remains  to  be
funded, and was ahead of its time when introduced. The current climate of opioid of misuse,
abuse, and diversion underscores the need for such a program. The American College of
Physicians  supports  NASPER,  as  well  as  other  organizations,  such  as  the  founding
organization  of  this  piece  of  legislation  The  American  Society  of  Interventional  Pain
Physicians (ASIPP).
Americans consume a remarkably large percentage of opioids prescribed worldwide. As a
leading  country  in  consumption,  the  United  States  only  makes  up  4.6% of  the  world’s
population. The U.S., however, consumes 80% of the world’s available opioids. The most
common opiate prescribed is hydrocodone, which the United States consumes 99% of the
world’s distribution of this drug. 34.2 million Americans greater than age 12 can claim use
of opioid for nonmedical use at some time in their life [45]. Nonmedical use of opioids is
staggering. According to DAWN data, 425,000 emergency department visits in 2010 were
a direct result of nonmedical use of opioids [46]. With more than 39,000 Americans dying
from drug poisoning in 2009, over 14,000 of those were from prescription opioids. But that
is  just  a small  component of  the problem. For each one death there were 10,000 admis‐
sions for abuse, 32 emergency department visits for misuse or abuse, 130 who abused the
drug or are addicted, on top of 825 nonmedical users for recreational purposes [47]. With
such ready availability and willingness to use opioids perceived as “safe”, the stigma of
controlled substances is removed. In the medicine cabinet, the risk of street drugs is not a
factor. Cocaine, heroin, even marijuana has a supplier for distribution of unknown character,
and the drug is always of unknown origin and purity. Not so with controlled substances,
regulated by the FDA. The danger, however, is real. Each passing year for the past fifteen,
the  opioid  death  rate,  opioid  treatment  admissions,  and  kilograms  sold  is  in  parallel
progression with the availability.
Opioid analgesic deaths exceeded cocaine and heroin deaths at an ever-increasing rate since
1999. Cocaine deaths are actually decreasing. Recently, heroin deaths have increased, but still
remains one-sixth that of opioid analgesics. Methadone is one of the cheapest and readily
available opioids, and is one of the leading drugs responsible for opioid fatalities. Methadone
is just 3% of opioid prescriptions in the United States but is associated with >30% of deaths
from opioids [48]. This staggering relationship could be attributed to methadone’s unpredict‐
able metabolism and half-life, and the numerous drugs that interact with methadone metab‐
olism and excretion.
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6. The evidence
The diversity of chronic pain conditions is extensive. Pain complaints range from headache
pain, spine pain, abdominal pain, myofascial pain, to extensive undefined widespread
discomfort. Chronic nonmalignant pain is rarely a single diagnosis. There is evidence that
controlled substances are helpful to control symptoms, improve function, and quality of life.
There is good evidence that opioids are strong analgesics, and have a role in chronic pain
management.
There is also extensive evidence that controlled substances are responsible for misuse, abuse,
and diversion. Particularly concerning is the concept of diversion. The DEA introduces a mixed
message to prescribers treating those with pain. First, the DEA is responsible for the availability
of the drug and will acknowledge that the physician is best prepared and trained to determine
whether opioids are indicated. The DEA will further point out that the physicians are at risk
for providing these medications, and may be unwittingly providing controlled substances to
inappropriate recipients. The word recipient is used over patient as often is the case of those
seeking drugs for distribution. These diverters are neither a patient, nor have a truly justifiable
chronic pain condition that would warrant controlled substances. If a physician is a partner in
diversion, knowingly or not, law enforcement has the option to prosecute.
• SS 841 knowingly or intentionally distributing or dispensing a controlled substance
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• No legitimate medical purpose for the prescription in that the same was not issued/filled in
the usual course of professional practice or was beyond the bounds of medical practice
• The conviction will be upheld even if the government does not present compelling evidence
that the doctor prescribed with malicious motive or the desire to make a profit
• Abbreviated or no medical history of physical examination is probative on the question of
whether a legitimate medical purpose exists
Prescribing to an individual with a nefarious purpose, even if you are unaware, may implicate
the prescriber and result in a legal action. The provider does not have to know, or profit from
the encounter. It simply has to happen. So the benefits of analgesia and improved function and
quality of life are now weighed against the abuse risk, misuse, and addiction threat. The
epidemic of chronic pain, its treatment with opioids, and the parallel morbidity and mortality
compels the prescriber to utilize all tools available to ensure that the proper prescription is
given to the proper individual for the proper purpose. The implications of this standard are
far reaching. Increased scrutiny can now be placed on individuals who prescribe beyond their
scope of care. An example might be an ophthalmologist providing diet pills to his mistress [49].
To the busy family practice physician that has not exercised proper caution, and only performs
a brief history or physical that does not support opioid use in the documentation, the risk/
reward benefit does not fall in the practitioner’s favor. It is not necessarily the intention to
provide substandard care, but time pressures are very real and patient needs and demands
can be extensive. A patient or individual that is persistent in aggressively obtaining controlled
substances knowingly does so against the physician’s common daily practice paradigm. Most
physicians are ill-equipped to confront a patient that exhibits inappropriate pain behaviors
and drug seeking activity. In some cases, a level of fear and bullying is injected into the practice
from a patient that is highly motivated to obtain a controlled substance. Evidence exists that
a physician is most likely to be non-confrontational, and accommodating, to diminish conflict.
This would include writing a prescription as the most expeditious and safest way to remove
this patient burden. Deyo, et al reported 61% of patients with low back pain in primary care
settings were on opioids at one point in the course of care [50]. Almost 20% of these were long-
term users in the primary care setting. Primary care physicians are the most common prescriber
of opioids, followed by surgical specialties. Primary care providers are also the source of most
immediate-release opioid prescriptions. Despite limited evidence that effective chronic pain
care therapy is enhanced with short-acting opioids, these highly abusable agents are com‐
monly prescribed [51]. Numerous guidelines also point out that long-term exposure to opioids
is of questionable benefit, with only small to moderate improvements in most pain states. By
contrast, evidence exists that poor patient selection is a leading cause of adverse outcome when
opioids are utilized to treat painful disorders [51].
Another concern regarding controlled substances, opioids in particular is the milligram dosing
the patient is exposed to. A group in Washington State recommends the dosing equivalent not
exceed 120mg of Morphine [52]. Proponents of education emphasize proper prescription
habits to realize establishment of medical necessity, which isn’t always obvious. Once need is
established, identifying the risk of misuse, abuse, and diversion, and utilizing strategies to
mitigate risk is good medical practice.
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Another important concept is acknowledging the multimodality approach to dealing with
pain, and subsequently reducing the opioid load. It has been demonstrated that interventional
techniques do address this concern and can reduce or eliminate the need for controlled
substances.
The typical patient referred to a pain management physician either comes from a surgical
referral or a primary care. As stated earlier, primary care is responsible for most opioid
prescriptions and often patients expect that opioid therapy will remain stable and be continued
at the current dosing. Over time, the patient develops a number of expectations as to entitle‐
ment of these drugs. Frequently referred to as “my hydros” or “my Oxys” for example, a high
level of anxiety is demonstrated when patients are educated about dose reduction, and exit
strategies from opioid-based therapy. This is an “opioid” stress test. Aberrant personality
behaviors can be confrontational, and emotional. Sometimes threats are made, and retaliation
may use the anonymity of social media, criticizing the physician in the numerous online rating
services, and even reporting the provider to the medical board. These retaliatory activities are
a demonstration of inappropriate illness behaviors, and reveals that the patient was a poor
choice for long-term opioid therapy. There is some truth to the belief that a good pain man‐
agement provider, with skill at controlled substance management, will have poor ratings in
social media and other physician rating services. The sad but true irony is that patients read
these online ratings, and make ill-conceived judgments about the individual provider, or the
care they have been rendered, owing more credibility to the rating sites than the patient/
physician relationship. This is a new form of physician slander, and there is virtually no
response that a physician can muster to defend their reputation. There is good evidence this
retaliation occurs.
Patients with non-cancer pain treated in the non-specialist’s office are often referred without
benchmarks. Benchmarks are understanding the benefit risk ratio of opioids and treatment
strategies at 3, 6, 9, and 12 months. These benchmarks should be straight forward and easy for
the patient to realize, with documentation to the medical record in the form of function and
quality of life indices. The patient might describe his/her benchmarks as simple as walking ¼
mile at 3 months four times a week, or even consider advanced lifestyle changes. Within these
benchmarks, the concept of the exit strategy is defined. This eliminates the misunderstanding
that opioids are an indefinite life treatment expectancy. There is no barrier to communication,
and documentation in the medical record is an aid to better understand treatment efficacy and
direction, demonstrating progression or regression over time.
With the initiation of opioids, there is a true and defined legitimate medical need, carried by
a diagnosis, supported by diagnostics, and usually physical exam findings. As subjective as
chronic pain can be, there are many tools available that document function and quality of life
indices, and ultimately the true effectiveness of a treatment profile. If opioids render little help
in improving movement forward in these benchmarks, or if benchmarks are never even
considered, it is difficult to justify continued opioid exposure. If the risk/reward benefit of
opioids is poorly documented, and the patient makes very little progress with poor lifestyle
choices, ultimately opioids are of little positive value. A patient may be unable or unwilling
to make an effort to change modifiable features in their health profile, and therefore it makes
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little sense to continue what is most likely a failed treatment paradigm. The multimodality
tools available, such as cognitive behavioral therapy, interventional techniques, durable
medical items, and advancing forward functional enhancements should have a tangible result.
If the goal of the patient is just to obtain a pill, it is unreasonable to expect significant im‐
provement at 3, 6, 9, or 12 months, and may signal inappropriate illness behaviors. There are
exceptions to each treatment plan. It is reasonable to allow flexibility with pain complaints as
there are multiple factors involved in the complex nature of chronic pain, where the diagnosis
rarely stands as a singular complaint. The goal however, is to be clear with the patient that
there is a plan. Consequences exist for the provider and for the patient if the plan is not realized,
and efforts to move forward ultimately fail. The patient comes to the physician for thoughtful
care, not just obtaining a prescription every month.
6.1. Recent studies supporting opioid therapy
Different combinations of opioids can add energy to effectiveness in the properly chosen
patient. A recent long term (52 week) study revealed sustained relief with 2 different opioid
preparations in patients with chronic non-cancer pain.[53] This study did not include a placebo
group but it did demonstrate sustained pain relief over a longer period of time than previous
studies. Another randomized trial of two opioids versus placebo has shown superior pain relief
with both active analgesics for chronic knee pain. [54] Newer agents are associated with less
drug liking, and the potential for abuse. Tapentadol has been reported to be superior to
oxycodone for osteoarthritis pain in terms of worker productivity and cost. Tapentadol is
available in 50 mg, 75 mg and 100 mg doses. The starting dose is 50-100 mg every 4-6 hours.
The maximum daily dose is 600 mg/day. [55] The abuse-resistant technology, Intac®, reduces
the diversion potential as well. Buprenorphine transdermal has been compared to oxycodone
over a 12-week period. A higher dose of buprenorphine (20 micrograms/hour) has been
demonstrated to be superior to oxycodone and low dose buprenorphine (5 micrograms/hour).
[56] Buprenorphine/naloxone sublingual film comes in 2mg/0.5 mg. 4 mg/1 mg, 8 mg/2 mg
and 12 mg/3 mg doses. It is important to note that naloxone does not reverse non-opioid
associated respiratory depression and sedation that might occur with barbiturates, alcohol, or
benzodiazepines.
6.2. The growing argument against chronic opioid therapy
Numerous recent studies have reported several problem areas react with chronic oral opioid
therapy. [57] Overdoses have increased significantly and are related to high doses and
prolonged duration of treatment. Opioids for arthritis pain have been associated with in‐
creased risk of fractures [58, 59]. The reason for this association is unknown. The DAWN data
teaches us that chronic opioid therapy is associated with increased emergency room visits.
Increasing opioid dosing has also been associated with increased risk of trauma in automobile
accidents. [60]
Among our military veterans, post-traumatic stress disorder and opioid therapy have been
associated with poor outcomes in veterans with chronic pain. [61]
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CLINICAL VIGNETTE. A 33 year old male arrives in the clinic late, claiming “car trouble.”
The individual has been asked to produce medications for a pill count, and a urine drug screen
is planned. This is a part of normal clinic operations. A previous attempt at having the
individual arrive for a pill count was thwarted when a family member died and services were
attended out of state.
Pain described is sharp electric-like pain, in a non dermatomal distribution, right leg predom‐
inant. Some left arm pain, and some paracervical discomfort is evident. Further descriptors of
the pain are vague and nonphysiologic. Pain is migratory, and often associated with back pain
and headaches. There is no neurological deficit and no focality.
This type of vague pain pattern reveals no specific characteristics which a diagnostic platform
can evolve. Often these pains are described as “myofascial or fibromyalgic.” A type of pain
that is poorly characterized and exaggerated, often inconsistent with examination findings. In
this particular case, according to the patient the only that helps the pain is Oxycodone, and a
specific dose is requested, “30s”.
When treating any type of pain, a diagnosis must precede a clinical pathway. In this particular
case, the only treatment that helps is an opioid-based pain medication in a young individual,
with very poorly characterized pain. Because it is migratory, and nonspecific, an interventional
procedure would have limited value. Allowing for age, and the lack of specific diagnostic
findings, suggests this pain is better treated with non-narcotic medication alternatives. The
pain described shares some characteristics of neuropathic pain and somatic character. A
generalized pain treatment plan would include medications that would have minimal
habituation potential, and poor drug “liking.” Gabapentin or Pregabalin would be a good
choice and could potentially diminish the central nervous system contribution assisting the
myofascial component, and carries minimal risk of misuse, abuse, or diversion. Drugs such as
Gabapentin and non-narcotic medication alternatives are also a good stress test. A patient that
is seeking for a specific drug therapy is challenged to try something new, and this care is
clinically sensible with less risk. If aberrancies evolve, the stress test would be positive.
Evidence suggests the alarming trend in abuse, misuse, and diversion overwhelms the most
powerful benefit from chronic opioid use, and argues against chronic exposure. As regulatory
restrictions were relaxed in the ‘90s, the trend to prescribe opioids has increased alarmingly.
Based on the patients self-report of pain, it is frequently the only tool we have to identify of
chronic nature. The humane approach when addressing a chronic pain condition was felt to
prescribe ever increasing milligram equivalents of opioids, as well as other adjunctive
medication. Evidence is lacking in non-cancer pain that pain conditions and function treated
with opioids actually improve when chronic in nature. Opioid induced hyperalgesia (OIH),
endocrine disorders, and potential poisoning highlight the better course of care that stress non-
narcotic options and minimize opioid exposure [62]. Specifically, an exit strategy should exist
when opioids are prescribed. If this is not always practical, benchmarks are usually a strong
predictor of positive or negative outcome.
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Obesity, depression, multiple symptoms and etiologies of chronic pain are predictors of poor
long-term outcomes for patients with chronic pain who are continued on chronic opioid
therapy. [63]
Additional risk factors related to poor outcomes for chronic pain patients have been reported
and include opioid use, older age, female gender, anti-social personality, government disabil‐
ity, and severe disability at initial evaluation and not working at discharge. [64] Furthermore,
opioid prescription for longer than 7 days has been reported as a risk factor for long-term
disability in workers with acute back pain. [65] The threshold to prescribe opioids in the
primary care setting is low, particularly with vague diagnosis states and external pressures.
Those that are treated with opioids for chronic pain often request ever increasing doses.
A 52-week study showed no major outcome difference between patient groups treated with a
stable opioid dose regimen versus an escalating opioid dose regimen. This suggests that higher
doses are not associated with additional benefit. Notably, 27% of the subjects in this study were
discharged due to misuse. [66]
Several studies have demonstrated significant analgesia with opioids for chronic pain, the
magnitude of pain relief is 20-30 %. However, 20-30% improvement is the same range as the
response to tricyclic antidepressants, gabapentinoids, duloxetine and tramadol. The functional
improvement associated with this analgesia is variable. Functional improvement is associated
with rehabilitation treatments such as interdisciplinary care; however, interdisciplinary
treatment is often not associated with pain relief. A weakness of many opioid studies is the
duration of therapy. The longest randomized, placebo controlled trials are weeks in duration
rather than months or years, which is often the duration of treatment with opioids used in
chronic pain. Also, patients are excluded from studies if they have psychiatric problems
including addiction.
Diversion of prescribed opioids is a known problem, particularly among younger patients. No
validated risk assessment tool exists and no failsafe way to prevent diversion has been found
that resolves or eliminates this risk. The risk of addiction is real. In a study of patients in
treatment for opioids, 39% reported being addicted to prescription opioids before switching
to heroin. [67]
Addiction and abuse are related problems that are often overlooked. The acute care setting of
a primary care office is a high risk environment to avoid this consequence.
7. Clinical vignettes
A patient presented to a pain center reporting a history of chronic pain secondary to brachial
plexus avulsion. He fully availed himself to all diagnostic and treatment modalities that failed.
The final treatment recommendation was a dorsal root entry zone radiofrequency ablation.
When advised that no guarantee of pain relief was made, he elected to continue opioid
treatment. He requested a letter supporting the prescribing of opioid for his condition. He used
the letter to secure prescriptions from multiple physicians.
The Evolving Role of Opioid Treatment in Chronic Pain Management
http://dx.doi.org/10.5772/58818
95
Lesson learned – urine drug screens may not detect multiple prescribing sources.
A patient with complex regional pain syndrome reported relief from 6-4 mg Hydromorphone
tablets every four hours. He stated he could get more relief from 7 tablets. A urine drug screen
showed marijuana and it was learned that he had obtained opioids from 150 physicians and
was eventually indicted on criminal charges related to selling prescription drugs. Then the
patient was reported to be deceased. When law enforcement officers go to his home, the patient
answers the door.
Lesson learned-urine drug screening is a useful part of an initial evaluation of patients who
report current opioid use.
A new patient was admitted to the hospital with a history of pancreatitis. The patients’ medical
history included being treated by a physician in another state with Hydromorphone 4 mg and
took 2400 pills per month in addition to high doses of long acting oxycodone. The prescription
was confirmed by a phone call to the dispensing pharmacy. The patient was treated with an
intravenous PCA pump and used minimal doses without any withdrawal symptoms or pain
escalation.
Lesson learned-The street value of prescription opioids is significant and physicians must
develop "street smarts" in order to avoid being duped into prescribing for patients who are
taking enough opioid to have a positive urine drug screen but selling the rest of their pre‐
scription as a means of financially supporting themselves. Quantitative and qualitative drug
testing on admission is important before opioids are administered by the emergency room or
hospital.
8. Adherence monitoring and the concept of accountability
As with any treatment plan, there are heralding moments in a patient’s course of care that
requires definitive action. Medical decision making in chronic pain is not always straight
forward. There is a strong subjective interpretation of the complaint, and the supportive
evidence of disease is not always visible. When the provider defines the need to initiate opioid
therapy or controlled substance management, any one of a number of findings could be entered
into a complex differential diagnosis. Often patients with pain suffer from situational anxiety
depression, and poor restorative sleep patterns. Comorbid disease states are the norm and not
the exception. Home and lifestyle intrusions involve many members of the patients surround‐
ing environment, with a psychosocial component that is often as complex as the painful entity
being treated. Formal and informal risk stratification may involve opioid risk tools, historical
precedent such as criminal history or misuse, abuse and diversion history, and is documented
at early stages in a patient’s encounter. The medical history or the Physician State Drug
Monitoring Programs (PDMP) might reveal a story of multiple prescribers, multiple prescrip‐
tions, and pharmacies [68-72]. These red flag incidences underscore the need for the previously
mentioned “plan”. Benchmarks that affect the patients function and quality of life status act
as a strong director of care and compliance, as well as the willingness to be actively involved
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in wellness to modifiable features and health profile. Adherence monitoring tracks conformity
and a patient’s willingness to follow principles and policies of controlled substance manage‐
ment. Ongoing adherence monitoring is time consuming and labor intensive. Often the patient
is introduced to the practice from primary care offices that are overwhelmed by the opioid
load and patient behavior, and given just enough medicine until the patient arrives for the
appointment. The false belief that this is less risky from an administrative position adds further
complexity to the first encounter. The patient expects that prescriptions will be written. The
provider must establish a relationship from in-depth historical investigation which can take
time. The appropriate patient for opioid therapy, or one that is at high risk, requiring an
elevated level of adherence monitoring, is decided early in the relationship. These are a new
set of rules for the patient, underscored by a patient care agreement, understood by the patient,
with no barrier to communication. This accountability and expectation requires the patient/
physician relationship to grow in trust, and these actions should not be seen as an intimidation,
but more of a “universal precaution” [73]. As much as we have employed universal precautions
for blood borne pathogens, we apply these principles to opioid risk intolerance. Every patient
that receives controlled substances is at risk for misuse, abuse, and diversion. The unique
patient population of an individual practice will best define what benchmarks are needed,
what precautions need to be taken, and when the patient is held to task. Also in place are
positive reinforcement scenarios, to help the patient understand that this is a part of what is
routinely done in the clinic, and necessary. A process of resolution is in place if the patient
deviates from the treatment plan, or presents a challenge with aberrancies or red flags in
controlled substance management. As previously mentioned, an opioid exit strategy may be
introduced from the very beginning of the relationship so that there are no misunderstandings.
Particularly true in painful states such as fibromyalgia, and vague musculoskeletal complaints
such as “low back pain”, opioids are not always the best choice. Other adjunctive medications
and non-narcotic options will decrease the opioid load, and many times increase relief cycling
and compliance.
The process of adherence monitoring is a directed care approach to ensure that the patient
receives the medication needed, in the dose necessary for therapeutic benefit, and that
legitimate need is met. The components of legitimate medical need, or necessity, are a
community standard, and not set by the DEA, or other regulatory agencies. Most agree that
legitimate need is intuitive, but nonetheless requires careful documentation.
Another principle of adherence monitoring is defining the diagnosis. Within the expected
activities of a history and physical, the formulation of a diagnosis evolves. In those that suffer
from chronic pain, the diagnosis may be very straight forward such as a herniated nucleus
pulpolsus (HNP), or as vague and challenging as interstitial cystitis, abdominal pain, myo‐
fascial pain, or headaches. The patient usually has pain that can’t be seen, touched, felt, or
measured and challenges the definition of legitimate medical need. Functional assessments,
impairment of activities, and the life experiences are documented to support clinical assump‐
tions. When opioids are introduced, the diagnosis often defines the length of exposure to an
agent and the expected opioid load. An HNP may be considered correctable or not, and a
headache may be cyclical or transient, and very real but invisible problems such as a traumatic
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brain injury or cluster migraine have driven some to suicide. Whatever the diagnosis, the
record will reflect a level of support for that diagnosis that further legitimizes the need for
opioid therapy. Risk is also assigned early, simply as low, medium or high defined by
individual practitioners tolerances and training. If the patient experiences surgery, such as
those that have isolated discogenic pathology, an exit strategy from opioids might be sooner
than the individual that has a recurrent or persistent painful disorder such as CRPS. Individ‐
ualized therapy requires documentation that exceeds a line or two of “I think it therefore it is”.
Once opioid therapy is initiated, as diagnosis directed, adherence monitoring begins.
Adherence monitoring is a complicated process of laboratory assessment, physical pill counts,
database interrogation, and good judgment. Ultimately, the provider and patient realize a safer
care environment.
9. Drug testing
There are four commonly utilized forms of drug testing – urine drug screening, specific drug
analysis, blood, hair sampling, and saliva testing. Drug detection periods can be in the minutes
to hours in blood, and similar with saliva. Urine is detected sometimes within minutes, and
lingers for many days. Sweat is similar, whereas hair might be detected hours through months.
Drug testing is not screening. Screening is a word that does not define necessity, which is
required for testing. The purpose of adherence monitoring, including drug testing, is to
strengthen the patient/physician relationship built on trust. Another purpose of urine drug
testing is to identify if the patient is taking medication prescribed, or not prescribed, and as
directed. Of the choices, urine drug screening is considered the gold standard. The results are
a product of the dose, metabolites, type of test used, characteristics of the drug, cutoff levels,
and the frequency of use.
Drug Duration
Amphetamine 2 – 4 Days
Methamphetamine 2 – 4 Days
Barbiturate 2 – 30 Days
Benzodiazepine Up to 3 Days
Cocaine 1 – 3 Days
Heroin/Morphine 1 – 3 Days
Marijuana – Chronic 30 – 70 Days
Marijuana – Occasional 1 – 3 Days
Methadone 2 – 4 Days, maybe longer (150 hours)
PCP – Chronic Up to 30 Days
PCP – Occasional 2 – 7 Days
Table 2. Duration for a positive screen
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Metabolites also play an important role in urine drug testing. The recent use of genetic testing
plays an important role in metabolite assessment. The importance of not only identifying the
current drug in testing, but its metabolite, is now realized as an impact item of adherence
monitoring. Transformation has occurred in healthcare that is just now being more defined in
clinical personalized care. Previously the pathology, physiology, as well as chemistry have
helped us understand disease. Today, the complexity of metabolic progression of clinical drug
therapy can require a suitable drug that can be individualized. With the model of genomics
and personalized care model, we can now follow the best course of care with specific agent
selection. If an individual’s hepatic metabolism does not support a 2D6 pathway, another agent
might be more desirable, utilizing another p450 enzyme pathway. The concept of pseudoad‐
diction has been reborn. Pseudoaddiction was introduced in the late ‘80s, based on the flawed
concept that individual reports of increased pain may occur because the patient is under dosed
[74, 75]. Now with the revelation of genetic metabolic variability, it can be demonstrated that
a chosen agent may be an inferior ineffective choice. Testing may suggest that it is not that the
drug is underdosed as with pseudoaddiction, but there is a poor metabolic progression to
activity of the chosen agent. For example, Hydrocodone is metabolized to normorphine,
norhydrocodone, hydrocodol, Hydromorphone, and hydromorphol. Oxycodone is metabo‐
lized to noroxycodone, Oxymorphone, oxycodols, and oxides. Some of these metabolites are
clinically active and potent, such as Hydromorphone in the case of hydrocodone. If the
metabolic pathway does not exist to metabolize hydrocodone to its metabolite, such as a weak
2D6 response, the efficacy of that drug will be significantly diminished. The rate of drug
metabolism may also be identified. Poor metabolizers to rapid metabolizers of a drug might
affect the chosen agent and its clinical activity. Over the next few years genetics will help us
tailor courses of therapy that are individualized, and help us improve patient care.
Urine drug screening and adherence monitoring is necessary to manage controlled substance
therapy, and diagnose misuse, abuse, and diversion. We test patients to monitor adherence,
support patient advocacy, uncover diversion, and addiction. We choose who to test as a process
of adherence monitoring, coupled with informed consent. Patients tend to declare themselves
during the course of treatment. Those that are resistant to certain drug or treatment profiles,
push specific drug requests. Any patient with aberrant behavior, or in recovery, would be a
high risk individual requiring enhanced monitoring. These tests are indicated when the
physician detects a clinical indication to do so to support decision making. Often, the clinician
will utilize a point of care sample, but confirmation usually follows if there is a red flag question
or unclear detection of a drug. Poorly identified drugs in point of care include Methadone,
Fentanyl, Oxycodone, and Tapentadol. Also GHB, anabolic steroids, designer drugs, inhalants,
and hallucinogens are difficult to detect. Point of care tests are based on competitive antibodies
and the drug saturates the antibody. Point of care is desirable due to the rapid turnaround
time, cost, and portability, but often requires a qualitative assay. Gas chromatography liquid
and mass spectrometry (GC-MS) is a common form of confirmation, but is expensive and can
take a number of days. Some point of care detection sensitivities are very accurate, such as
cocaine, with a primary metabolite benzoylecgonine. There is low cross reactivity with other
substances, and is considered very reliable at point of care. Less so are nonspecific opioids, as
well as synthetic opioids. When assessing a urine test, positive results require close analysis.
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There are many cross reactants, and positive results do not always mean an illicit substance
has been ingested. For example, a morphine positive urine drug screen may also result from
a metabolite of codeine, which is morphine. The reverse is not true. Also seen is the possibility
of positive THC, when the patient has a prescription for Marinol. To ensure the validity of a
specimen, which can be tampered by dilution and adulterants, adding verification with
creatinine, pH and temperature are applied. High volume ingestion of water, such as two
quarts, might produce a negative result with the cutoff level being diluted to a negative result.
Even the internet offers tools to pass a drug test. Most are adulterants and oxidants.
Drug
Screening cut-off
concentrations ng/mL
urine
Confirmation cut-off
concentrations ng/mL Urine detection time
Immunoassay (I)
Chromatography (C)
Hydrocodone 300 50 1 – 2 days I & C
Oxycodone 100 50 1 – 3 days I & C
Morphine 300 50 3 – 4 days I & C
Methadone 300 100 5 – 10 days I & C
Hydromorphone 300 100 1 – 2 days I & C
Meperidine 300 100 1 – 2 days I & C
Codeine 300 50 1 – 3 days I & C
Benzodiazepines 200 20 – 50 Up to 30 days I
Barbiturates 200 100 2 – 10 days I & C
Marijuana 50 15
1 – 3 days for casual use;
up to 11 weeks for
chronic use
I & C
Cocaine 300 50 1 – 3 days I & C
Amphetamine 1,000 100 2 – 4 days I & C
Methamphetamine 1,000 100 2 – 4 days I & C
Heroin* 10 25 1 – 3 days I & C
Phencyclidine 25 10 2 – 8 days I & C
*6-MAM, the specific metabolite is detected only for 6 hours.
Table 3. Urine drug testing: Typical screening and confirmation cut-off concentrations and detection times for drugs
of abuse.
Adherence monitoring with urine testing is just one technique. Pill counts also reveal compli‐
ance. Depending on the personality of the patient, motivating features of their personality, and
their apparent risk – mild, moderate, or high risk – different delivery systems might even be
considered. The common and erroneous belief that a patch system is a significant improvement
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in safety is not borne out in the reality of pain care. These patches can be utilized nefariously,
and have street value. It is recommended that spent patches associate with an accountability
system, such as placing them in an envelope, or on a piece of paper with each patch dated, and
returned to the clinic for inspection. In the case of Fentanyl, there is significant Fentanyl left in
the patch after three days. Patients who say that their patch does not work after “two days”
might be given more patches, with the increased potential for diversion. If diversion is not
suspected or borne out when a properly dosed drug is ineffective, the argument for genetic
testing could be made. Poor or rapid metabolism is possible, and alters the effectiveness of the
chosen agent. Those at high risk, such as those that are on Medicaid or disabled, have a history
of substance abuse, bipolar, borderline personality, chaotic lifestyle, and alcoholism, and those
that exaggerate symptom response, require significant adherence monitoring. Drug testing
may be more frequent than two times a year, as are pill counts and other adherence monitoring
techniques. Plans must be in place with written agreements that include informed consent and
therapeutic boundaries understood by the patient, family members, and relevant individuals,
such as those with power of attorney. There are some patients that controlled substances just
are not safe enough to give, or will be misused, in which the clinical course of care begs another
form of treatment such as interventional medicine, manual medicine, or other pharmacologic
manipulations. Those that have deviations from the patient care agreement, adulterance of the
urine, misuse, abuse, or divert, should be introduced to a pathway in their best interest. Simply
discharging the patient is unacceptable. Offers to afford the patient care in another arena are
considered good medical care, and referrals to psychiatry, addiction medicine, methadone
clinics, and other community services are strongly urged. The process of abandonment cannot
be ignored. The reality of those that use controlled substances is that most make mistakes. This
does not mean that they are bad people, or do not have a legitimate medical illness that can
be treated by other means.
10. PDMP
The prescription database management systems or programs (PDMP) that are seen in nearly
all 50 states identify the origin of the prescription, the physician, and the details of the
prescription such as number of pills, refills, and date. Utilizing this information, the practi‐
tioner will then determine if the patient is utilizing medication properly, if violation of patient
care agreement is evident, and ensure that compliance is in place.
10.1. Communication
Pain care in modern medicine is an expectation that has even been assigned its own vital sign.
Unlike a number of years ago, care providers are becoming more enlightened regarding the
necessity and societal need for pathways of relief in those that are impaired by pain. Methods
and techniques of pain treatment are as varied as the providers that care for these individuals.
A full spectrum of care is available today, from manual therapy to interventional medicine,
and pharmacologic strategies have many choices. Occasionally the clinician is challenged to
provide adequate care, but lacks the availability of the proper therapeutic option. Chronic pain
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care by its very nature will be treated by multiple specialties, each offering its own solution.
The Code of Ethics published in the American Medical Association 1847 “from the age of
Hippocrates to the present time, the annals of every civilized people contain abundant
evidence of the devotedness of medical men to the relief of their fellow creatures from pain
and disease” [76]. By the very nature of pain and its associated diagnosis, cross specialty
cooperation is necessary to obtain the best outcome. It is therefore, the duty of a care provider
to offer pain care and relieve suffering. Edwards, in Pain and the Ethics of Pain Management
1984 stated “there is a duty to do all that can be done within the limits of current medical
knowledge and available resources to relieve all the pain and suffering which can be alleviat‐
ed” [77]. Herein lies the problem. Not all chronic pain disease states can be clearly defined,
unlike other medical disease states. Pain is really the reflection of an individual’s own
subjective interpretation that has a number of biopsychosocial influences.
Chronic pain care is also constrained by the financial and medical/legal environment. From a
regulatory perspective, the pain care provider may find road blocks to address an individual’s
pain. Fear of reprisal or a negative peer opinion will often lead to under treatment of pain.
Other providers don’t find an interest in treating pain because of the vagarity of an individual
diagnosis and lack of diagnostic tools available to assess the patient that has pain. Pain is one
of the most common complaints in a physician’s office, and is often the lowest point of focus.
Pain is more than a symptom; it is also reflective of a disease state or illness, and is rarely a
singular disease entity. Comorbidity should be expected. This further complicates the treat‐
ment pathway and promotes polypharmacy. The patient develops a “personality of pain”
responsible for inflicting emotional, and neuropsychiatric impairment. This psychological
decay further leads to decline in function. The complexity of the pain diagnosis can change
the identity of an individual that diminishes the feeling of wellness from every aspect of an
individual’s life. Situational depression and anxiety are deleterious problems in the patient
suffering from pain, and are often a comorbidity. Magnified by the lack of cohesion in pain
care, these different facets of pain diagnosis often go untreated, diminishing the potential
effectiveness of a prescribed treatment course. It is not that a certain medication pathway, or
interventions “don’t work”, it is more likely that the individual patient is not treated as a whole.
This fragmented care is costly to the patient and society.
Over the past ten years the prevalence of chronic pain has remained a consistent challenge for
providers and patients. The advances in treating pain primarily revolve around pharmacologic
management, interventional tools, and musculoskeletal therapy. The realities of our evolving
healthcare delivery systems may continue to limit access to this already under treated
population. Now considered a fifth pathway, pain itself will be unlikely to support a priority
position in the healthcare hierarchy. With innovative payment programs such as ACOs, and
the remnants of managed care, priority will be given to chronic life-threatening disease states,
and then followed by those with progressive disabling afflictions. Chronic pain, which is many
times disabling, is not a life-threatening entity. The pain provider will be challenged to render
effective care, increasing function and quality of life, and minimizing risk in the new order.
With rising healthcare costs opioid use has increased. Escalating opioid use has a direct
relationship with adverse consequence. Considered inexpensive, opioid therapy is actually
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quite costly. The potential for abuse events and long-term use may be significantly higher than
adjunctive or interventional options.
Clinical Vignette. A new patient complains of low back pain. He was referred for medication
management. Payer source is Medicaid, he does not work, and the MRI reveals modest
degenerative changes. He is a smoker, and recently divorced. The exam reveals nonphysiologic
findings and otherwise unremarkable.
At initial visit, an intake questionnaire suggested possible use of a controlled substance that
was supplied by a family member, and a urine drug sample is obtained. Within the sample,
nonspecific opioid at point of care was found, and was positive for THC.
The patient is requesting a pain prescription, and is persistent as to the need to obtain “Oxys”
so he can go look for a job. He has been on these before and that is the only thing that works,
specifically defining the medication needed that doesn’t have Acetaminophen, which upsets
his stomach.
A number of issues arise with this vignette, specifically the lack of a clear pain diagnosis. A
diagnosis is a necessary component of the controlled substance management plan, and
necessary to the medical record. Low back pain is a common complaint, but it is just that, a
complaint or a symptom, not a diagnosis. The exam rendered very few clinically relevant
findings and the supportive imaging was not remarkable. The patient is specific on the type
of medication wanted, in its pure form, and has a chaotic home life. The original history did
not bring forward the use of hydrocodone, which was extracted after the point of care testing
found unexpected opioids, and THC, illegal substances evident. This is a red flag encounter.
A number of inconsistencies and elements of inappropriate seeking behaviors are evident. This
coupled with the lack of clear diagnosis, the willingness to take someone else’s medication, is
counterproductive to establishing a firm patient/physician relationship built on trust. Even the
fact that the individual is on a government assistance program increases the risk of misuse.
The clinical scenario would suggest to many providers that this patient needs to be discharged
from the clinical environment. This might be a common approach, but it is not the best
approach. An individual that has red flags is an individual that requires adherence monitoring
and advanced care. With the epidemic of opioid prescription drug deaths, it is this type of
individual that does need an intervention. Simply dismissing this individual places the patient
and community at risk. This individual will doctor shop, going from practice to practice until
they are satisfied, and likely return to that provider with increased requests. The chaotic
lifestyle will usually evolve into expectations of a prescription when pills are lost or stolen.
The use of controlled substances for recreational purposes was not realized to the full extent
until the era of the late ‘90s. Prior to 1996, DAWN and ARCOS data did not reveal a particular
trend of abuse, misuse, or diversion. That same period of time medical use was increasing
rapidly, but there were no particularly revealing trends that divulged the urgent need for
increased scrutiny of these agents. Some believe that the increased use of opioids is enhanced
realization that chronic pain is undertreated. Recently, however, the trend is more alarming.
Even though there is a slight reduction in opioid use overall, misuse has increased.
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As with any treatment, the risk/reward benefit is carefully considered prior to initiating
therapy. In the case of this vignette, or any scenario where opioid management is considered,
the conscious decision to prescribe or not prescribe is based on clinical support. The expectation
is that opioids will increase function and quality of life, but that does not always seem to be
the case. Despite evidence that opioids do not improve quality of life and may actually increase
disability, the use of opioids and controlled substances for the subjective complaints of pain
remain robust. Further underscoring this irony is that chronic opioid use lacks evidence
supporting use, an abundance of evidence exists that these agents are risky and in certain
patient populations, dangerous. Despite remedial efforts at educating the medical community,
widespread opioid use promotes misuse, abuse, and diversion. In the case of low back pain,
a physician that is pressured in the primary care office for time, and a patient’s insistence on
obtaining a controlled substance, it is often easy to prescribe and avoid confrontation. Our
society is becoming increasingly tolerant of previously forbidden drugs. We are entering into
the marijuana era, where states assess the tolerance for recreational use, and legalize the drug
for sale and distribution. Patients will then perceive, as many do now, that marijuana is an
innocent drug. Marijuana is, however, a drug of abuse. Impairment is a side effect of the drug,
just as alcohol and benzodiazepines. Despite states opinions, marijuana is illegal at the federal
level. Most providers have entered into an agreement with the Drug Enforcement Adminis‐
tration that they will prescribe by community standard, and will withhold prescriptions when
illegal drugs are used. At the federal level, marijuana remains a schedule I drug, where no
medical use is defined. Those that prescribe have a DEA certificate that is federal, not controlled
by the state, which establishes a legal and ethical question between patient and provider. If a
patient perceives marijuana as part of their necessary routine, is it legal and ethical for a
physician to prescribe a controlled substance? This question has not been answered.
Again the risk/reward benefit should be considered foremost in a medical practice. The
common denominator of the provider and the patient is the healing interaction in the clinical
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construct as understood by the patient and clinician equally. When one of the parties, in the
case of the vignette, is outside of the expected clinical norm, care options are limited, such as
opioid use. Controlled substance management is the most likely choice to be eliminated when
aberrancies are noted. Many care options in chronic pain medicine are discretionary, and
believe that a patient’s pain is “real.” Pain is subjective, with physiologic and psychologic
comorbidities, and requires the provider to acknowledge the difficulties of treating those in
pain. The prescribing physician and the patient enter a cooperative agreement. Each under‐
stands expectations and boundaries.
11. Regulatory agency pressure
Regulatory agencies such as state medical boards in the United States, the US Food and Drug
Administration, as well as law enforcement agencies are under pressure to crack down on
over-prescribing and "pill mills". The Physicians for Responsible Opioid Prescribing (PROP)
have recommended changes in the labeling indication for opioids [78]. They have recom‐
mended limiting the labeling indication for opioids to limit the duration of opioid therapy to
90 days and limiting the dose to 100 mg/day of morphine equivalents. This expert group also
recommends limiting opioid to severe pain rather than moderate pain. These recommenda‐
tions do not apply to end of life care. The consequences of labeling changes such as these would
make chronic opioid therapy an "off-label" use and many physicians would be reluctant to
continue prescribing chronic opioid therapy that is considered "off label". If the FDA adopts
the recommendation of the petition, signed by experts, it would create a new and unfavorable
environment for practitioners and patients. Access to pain care would be reduced.
11.1. Clinical situations as an Alternative to Chronic Opioid Therapy
Clinical Vignette. A rancher takes three hydrocodone per day for osteoarthritis of the knees
for years. His orthopedic surgeon wants to wait a few more years before replacing his knees.
The patient does not drink alcohol or use other controlled substances, and he continues to work
cattle on his ranch. He breaks his own horses.
Some patients do well with opioids, and do not require escalating doses. Without significant
dose escalation, they retain a high level of function. In this particular individual, the diagnosis
is clear, there have been no discernable side effects, and he is able to continue with his activities
of daily living, enjoying a high level of function despite his arthritis.
An elderly patient with spinal stenosis has a history of gastrointestinal bleeding felt to be
triggered by anti-inflammatory agents, and reports no significant relief with non-narcotic
medication alternatives, including maximum dose of acetaminophen. She has been intolerant
of tricyclic antidepressants and gabapentinoids. She is unable to afford non generic therapy.
Hydrocodone is intolerably constipating, but she is able to function with Tramadol, and is
being treated in an interdisciplinary environment.
This particular patient is an individual that has failed non-narcotic options, but has a spine
that may be treated with an interventional approach. She may be a candidate for caudal lysis
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of adhesions, or the recently introduced minimally invasive lumbar decompression (MILD)
procedure, or both before proceeding with further spinal surgery. Certain patient populations
are felt to be poor candidates for opioid therapy or unable to tolerate the side effects. Patients
with chaotic lifestyles, post-traumatic stress disorder, and certain types of anxiety and
depression lead to misuse and potential abuse. Habituation and lack of efficacy are significant
problems with opioids. Opioids have been reported to interfere with the treatment of anxiety,
and may lead to an actual decline in quality of life, and promote pain and disability. Other
groups with obesity, multiple symptom etiologies, and vague pain complaints that do not have
a clear substantiated diagnosis are also less attractive candidates for opioid therapy. Risk items
might include older age, female, antisocial personality, government disability, severe disability
initial evaluation, not working at discharge, and previous history of misuse, abuse, and DWI.
As might be expected, the longer a person is out of work the less likely they are to return.
Opioids prescribed for longer than 7 days have been reported a risk factor for long-term
disability in workers with acute back pain. The 52 week study showed no major outcome
differences between patients treated with stable opioid regimen versus escalating opioid dose
regimen. Higher doses are not always associated with additional benefits, and the potential of
introducing opioid-induced hyperalgesia is another item of concern when utilizing opioids in
chronic therapy. This 52 week study had a dropout rate of 27% due to misuse, which is very
consistent with a number of other studies that reveal opioids are misused by 20-25% in various
patient populations. A retrospective study found no correlation between opioid dose and pain
severity in patients with chronic pain who took opioids for an average of 704 days. These
patients were treated with higher doses in response to elevated pain complaints, and it was
observed that patients on lower doses reported less pain. Conclusions are difficult to discern
between the potential for hyperalgesia, versus dosing resistance.
A unique population that is emerging as a significant opioid use category is pregnancy. Of the
1.1 million pregnant women enrolled in Medicaid, 23% filled an opioid prescription in 2007.
This is up almost 19% from 2000, according to a recent study published in Obstetrics and
Gynecology [79]. It is estimated that 1 in 5 women use opioids during pregnancy. Another
study revealed 500,000 privately insured women found 14% were dispensed opioid pain killers
at least once during their pregnancy. The rate of opioid prescriptions was the highest in the
south and the lowest in the northwest. In the study, of the women enrolled in Medicaid, 41.6%
of pregnant women in Utah were prescribed opioids, and Oregon had the lowest at 9.5%. This
regional discrepancy does not reflect differences in pain states, but the willingness of the
provider to prescribe opioids. Opioids do not have a sufficient number of studies to demon‐
strate safety in this population. Increasing use of opioids during pregnancy may lead to
neonatal abstinence syndrome. It is likely that society expects some type of medication be
utilized for pain relief when acetaminophen is not effective. Possibly explaining the increased
use is that opioids are one of the few choices other than medication for relief during pregnancy.
Diversion of prescribed opioids remains a rising problem with the young people. Among
persons aged 12 older who used pain relievers nonmedically, 55% report they received the
drug for free from a friend or a relative, while another 11% bought the drug from a friend or
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a relative. 7 million, 2.7% of the population, persons aged 12 or older used prescription-type
drugs nonmedically in the past month.
5 million of these used pain relievers. There is no validated risk assessment tool that exists to
clearly identify and prevent diversion. Chronic pain may be the complaint, but in one study
almost 40% of those addicted to prescription medications eventually switched to heroin [79,80].
12. Overdoses
Overdoses occur, and are a feared complication of controlled substance management. Over‐
doses on opioids alone are relatively uncommon. Usually overdoses occur with polypharmacy,
other offending agents usually being benzodiazepines, or barbiturates. Barbiturates, mixed
with alcohol, is a combination with opioids that is extremely hazardous. Although opioids are
the most common drug class associated with overdose, the combination of opioids with
benzodiazepines and other psychotropic drugs are associated in up to 10% of overdoses. A
study in 2006 of West Virginia overdoses was found to be associated with nonmedical use and
diversion of opioids, only 44% of victims had been prescribed the found drug.
13. Informed consent
Informed consent is not an optional endeavor in the clinical setting. It is a process, in which
there is a communication, established clearly, with no barriers to communication between the
physician and the patient. Many times the patient is not the one that would be the necessary
recipient of informed consent, such as in the event of a patient rendered insensible, under the
context of a court order, or power of attorney. Informed consent is an interrelationship between
the patient, physician and society. It is a process that involves many steps, and the physician
is ultimately held responsible for breakdown in informed consent.
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The process of informed consent is both a legal and clinical action and is a process of protecting
the communication lines, and avoids misrepresentation of understanding, and ultimately
communication failure. It assumes the physician is an educator to the patient, family, and
medical community, and requires that all aware are in acceptance, and aware of potential risks
and benefits to a particular treatment or therapy. Informed consent is a necessary element of
controlled substance management. Poor communication resulting in altered expectation of the
family and patient is a leading factor in the generation of lawsuits. Informed consent reduces
this risk and assumes that standard of care between a reasonable prudent physician, nurse,
physician’s assistant, nurse practitioner, or other provider exists, that has similar training.
Under similar circumstances these providers would react to medical issues that establish the
standard. A physician has a duty to disclose to his patient the risk of injuries that might result
from proposed course of treatment. The American Medical Association guidelines define the
physician should
• disclose the patient diagnosis if known
• the nature of proposed treatment or procedure
• the risks and benefits of proposed treatment or procedure
• alternatives
• the risks and benefits of alternative treatment
• the risks and benefits of not receiving or undergoing the treatment.
These guidelines are not requirements, but this list effectively establishes a standard of care
by which a physician’s disclosures are measured. In general, a physician does not need to
advise a patient of every conceivable risk but only the substantial risks must be disclosed. That
might be what a physician would reasonably know to be a part of the treatment course, and
allowing the patient to decide whether they would want to consider moving forward.
Informed consent may be verbal, but documentation establishes a better pathway to defend a
dispute. Care must be taken that the individual who is providing informed consent is ade‐
quately trained to understand the importance of this task. The patient should have a clear
understanding of the implications of informed consent, and ample time to ask questions, and
engage in dialogue that addresses the patient’s concerns.
Many guidelines now recommend obtaining separate and specific informed consent for opioid
treatment. Warning patients of addiction risks as well as overdose and diversion are important.
The Federation of State Medical Board rules state:
"Informed consent documents typically address:
• The potential risks and anticipated benefits of chronic opioid therapy.
• Potential side effects (both short-and long-term) of the medication, such as constipation and
cognitive impairment.
• The likelihood that tolerance to and physical dependence on the medication will develop.
• The risk of drug interactions and over-sedation.
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• The risk of impaired motor skills (affecting driving and other tasks).
• The risk of opioid misuse, dependence, addiction, and overdose.
• The limited evidence as to the benefit of long-term opioid therapy.
• The physician's prescribing policies and expectations, including the number and frequency
of prescription refills, as well as the physician's policy on early refills and replacement of
lost or stolen medications.
• Specific reasons for which drug therapy may be changed or discontinued (including
violation of the policies and agreements spelled out in the treatment agreement)."
14. Opioid agreements
An opioid agreement is sometimes called “a contract.” The opioid contract implies a legal
component, so better terminology is an “agreement” between the prescriber and those
receiving the controlled substances. The opioid agreement, or controlled substance agreement,
is an understanding between all parties that there will be one source of prescribed medication
that is of controlled nature, and one dispensing pharmacy. There can be some practical
adjustments, but the reality is that it is necessary to have this document in place so there is no
barrier to communication.
Opioid agreements encourage patients to avoid dose escalations, multiple prescribers and
pharmacies, and inform patients of opioid tapering and discontinuation of opioid may occur
if necessary.
The Federation of State Medical Board rules state:
"Treatment agreements outline the joint responsibilities of physician and patient and are
indicated for opioid or other abusable medications. They typically discuss:
• The goals of treatment, in terms of pain management, restoration of function, and safety.
• The patient's responsibility for safe medication use (e.g., by not using more medication than
prescribed or using the opioid in combination with alcohol or other substances; storing
medications in a secure location; and safe disposal of any unused medication).
• The patient's responsibility to obtain his or her prescribed opioids from only one physician
or practice.
• The patient's agreement to periodic drug testing (as of blood, urine, hair, or saliva).
• The physician's responsibility to be available or to have a covering physician available to
care for unforeseen problems and to prescribe scheduled refills."
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14.1. Sample Opioid Agreement
The following agreement relates to my use of controlled substances including, but not limited to “narcotics/opioids,”
to treat chronic pain. I will be provided with the prescriptions only if I understand and agree to the following:
_____1. I understand that, depending on the drug and dose, I can become physically dependent on the medication
and can develop withdrawal symptoms if the medication is stopped suddenly or the dose reduced rapidly. Although
the risk is small there is a chance of developing an addiction to controlled substances if I am placed on them to help
control my pain.
_____2. Controlled substances can cause sedation, confusion, or other changes in mental state and thinking abilities. I
understand that the decision to drive while I am taking controlled substances is my own decision, and I agree not to
be involved in any activity that may be dangerous to me or someone else such as driving or operating any dangerous
equipment, working in unprotected heights or being responsible for another individual who is unable to care for
himself or herself if I am in any way sedated, feel drowsy or am not thinking clearly.
_____3. I will not use any illegal substances including, but not limited to, marijuana and cocaine. I will not drive while
impaired with alcohol or other substances.
_____4. The Receiving Controlled Substance Policy regarding the dispensing of controlled substances requires that I be
seen regularly and I agree to make and keep my appointments. I will advise my doctor of all other medicines and
treatments that I am receiving.
_____5. If the medication requires adjustment, an appointment must be made to see the doctor. No adjustments will
be made over the telephone. My careful planning is required. I understand that medication refills and adjustments are
done during office appointments. I must stay with the prescribed dosing so that I do not run out of medication early. I
understand that the Refill Policy is NOT to prescribe early. I agree that I will use my medication exactly as prescribed
and that if I run out early, I may go without medication until the next prescription is due, possibly resulting in
withdrawal symptoms.
_____6. I understand that the prescriptions are my responsibility once they are placed in my hand and that if anything
happens to my prescription (lost, stolen, or accidentally destroyed), I may NOT receive a replacement from my
physician. I am expected to file a police report if my medication is stolen. I will be prepared to bring in a copy at my
next REGULARLY scheduled visit.
____7. My physician will prescribe whatever medication he/she is comfortable with and thinks is best; he/she is not
under any obligation to prescribe any specific medications.
____8. I am aware of the possible risks and benefits of other types of treatments that do not involve the use of opioids.
The other treatments discussed include: injections, therapy, and surgery (if indicated).
____9. I agree to come to (Insert Facility Name) with my medication on the same day that I am called and submit to a
pill count, and/or urine or blood screening to detect illegal substances or confirm proper use of prescribed
medication. The call to come to (Insert Facility Name) can be made either randomly, or if a concern arises. I may be
required to bring my unused medication routinely to each office visit. If I do not have insurance or my insurance
denies testing, I will be responsible for the cost of the test.
____10. I give permission to (Insert Facility Name) to call any pharmacy or another health care provider at any time,
without me being informed, to discuss my past or present use of controlled or illegal substances.
____11. I will not use my pain medication in higher than prescribed amounts for new problems that arise (toothache,
surgery, etc.) unless authorized to do so by (Insert Facility Name). I will inform my other doctor(s) of my use of
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medication for chronic pain, and I will inform (Insert Facility Name) if another physician prescribes controlled
substances for the acute problem and I will not mix the medications unless advised to do so by a medical professional
either (Insert Facility Name) or the prescribing provider of the acute medication. I understand this is only in acute
situations and documentation of the situation must be provided to (Insert Facility Name). My doctor at (Insert Facility
Name) is my primary doctor with regard to my pain medications. If there is a medical emergency (e.g. broken leg,
surgery requiring post-op pain medication, dental procedures, etc.), another doctor may prescribe pain medication to
me, but I will advise the prescribing doctor of my care at (Insert Facility Name) including my binding contract, and
authorize the doctor to disclose information to (Insert Facility Name), and I will also notify my doctor at (Insert Facility
Name) of the medication and the dosage as soon as the emergency occurs (if after hours, it’s my responsibility to call
first thing the NEXT business day). It will also be up to my provider at (Insert Facility Name) to determine if it was a true
emergency requiring additional medication, if not my contract from this facility may be voided.
____12. (Females only) Because of the risks of certain medications to unborn children, I will inform all physicians,
obstetrician/gynecologist and (Insert Facility Name) immediately if I become pregnant or decide to try to become
pregnant. I am aware that should I carry a baby to delivery while taking these medicines; the baby will be physically
dependent upon opioids. I am aware the use of opioids is not generally associated with risk of birth defects. However,
birth defects can occur whether or not the mother is on medicines and there is always the possibility that my child will
have a birth defect while I am taking an opioid. I am also aware that opioids may alter my hormones as well.
_____13. (Males only) I am aware that chronic opioid use has been associated with low testosterone levels in males.
This may affect my mood, stamina, sexual desire and physical and sexual performance. I understand that my doctor
may check my blood to see if my testosterone level is normal.
_____14.My physician can wean me off of controlled substances at any time if he/she feels that it is in my best interest.
(Insert Facility Name) will follow relevant laws when weaning me off of my medication. The weaning process can
result in withdrawal symptoms. If I am weaned off, (Insert Facility Name) staff may inform my other health care
providers as to the reasons for the weaning. (Insert Facility Name) may send me to a detoxification facility if indicated.
I understand that (Insert Facility Name) will not be responsible for weaning me off of Methadone if I present with that
in my system.
_____15. Abstinence Syndrome (Withdrawal Syndrome): Stopping my opioid, anti-seizure or antidepressant
medication abruptly may result in withdrawal symptoms (flu-like symptoms, GI distress, diarrhea, sweating, heart
palpitations, and rarely seizures or death). I should wean from my medications rather than stopping them abruptly. It
is my responsibility to keep up with the amount of medication I have. I will make my appointments accordingly, before
I run out.
_____16.I understand that in general I may be weaned off of my medication or my drug therapy may be terminated at
the discretion of my physician if any of the following occur:
a)It is the opinion of my physician that controlled substances are not very effective for my pain and/or my functional
activity is not improved.
b)I misuse the medication.
c)I develop rapid tolerance or loss of effect from this treatment.
d)I develop side effects that are significant and detrimental to me.
e)I obtain controlled substances from sources other than my provider at (Insert Facility Name) without informing him
or her.
f)Pill counts or test results indicate the improper use of the prescribed medication or the use of other drugs, and/or I
fail to submit to such counts/tests on the day that I am called.
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g)I am arrested and/or convicted for a controlled or illicit drug violation including drunk driving.
h)Any violation of this agreement.
_____17. I further understand that my drug therapy will be terminated or detoxification in a controlled environment
will be required if I give away, sell, distribute and/or transport with the intent to sell or dispense my medication.
_____18.I choose to use _________________________________________ Pharmacy, located at
___________________________________________, for all of my pain medication prescriptions. I will not fill partial
prescriptions if my pharmacy does not stock the full quantity of medication. If I change my pharmacy for any reason, I
agree to notify my pain physician.
I have read the above Agreement, understand the Agreement, have had all my questions concerning this Agreement
answered to my satisfaction, and I agree to abide by the terms of this Agreement if I am placed on controlled
substances (including, but not limited to narcotic analgesics). I have received a copy of the Agreement. By signing this
form voluntarily, I give my consent for the treatment of my pain with narcotic/opioid pain medicines.
______________________________ _______________________
Patient Date
______________________________ _______________________
Physician Date
______________________________ _______________________
Witness Date
15. Screening questionnaires
The screening questionnaires available for controlled substances are often referred to as opioid
risk tools, or ORTs. A number of these exist online, and can be referenced for use. Some are
validated and some are not, but they are typically used to identify the risk of addiction, abuse,
depression, anxiety, potential for diversion, and overdose among others. Also, comorbid
diseases such as depression may be screened for. The usefulness of these tools is not known.
They do not identify illegal use, abuse, or diversion.
16. Opioids and delivery systems
A number of synthetic and semi-synthetic opioids are utilized to control pain. The patch
delivery system, uniquely associated with Fentanyl, has now been adopted with buprenor‐
phine. Newer molecules such as Tapentadol utilize ascending and descending central nervous
system pathways for pain control. Hydrocodone and Oxycodone are among the most com‐
monly used opioids in the United States, and morphine is still considered the gold standard,
of which the potency and efficacy of the opioids are measured. Methadone is a synthetic opioid
that is inexpensive and long-acting. Methadone has been used for years to prevent patients in
recovery from relapsing and using heroin and other street-borne opioids. Methadone clinics
typically require patients to come to the clinic daily to receive a daily dose which prevents
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overdose. Methadone is associated with its own unique problems including cardiac arrhyth‐
mias, and the interaction that it has with many drugs through hepatic metabolic pathways.
This makes the half-life of Methadone variable, introducing the drugs unpredictability to the
pain care community. Methadone is considered a drug of enhanced risk in this regard. If used
at all, Methadone doses should be initiated at low levels and monitored closely.
17. Fentanyl
Fentanyl is an opioid of choice in patients with renal failure or allergy to morphine. Transder‐
mal patch preparations have been associated with less constipation compared to oral opioids,
and the delivery system assists in adherence if pills are problematic. However, the steady state
of fentanyl may not occur until 12 hours after a dose change so it is not a good sole agent in
acute pain settings where dose adjustments need to be made frequently. Even small doses have
been associated with respiratory depression and death. Recently, Fentanyl has gained street
popularity by mixing with heroin.
Transdermal fentanyl is now available in a lower dose of 12 micrograms per hour. Fentanyl
oralets are available in 100 microgram preparations and fentanyl oral film is also available for
oral mucosal administration. The buccal absorption is utilized in cancer pain therapy, and
onset is rapid.
17.1. Opioid conversion
Patients may need opioid conversion to another opioid for a number of reasons. Sometimes
cost is a factor, or rotation to another agent for metabolic reasons such as tolerance and
metabolic inefficiency. Multiple opioid conversion charts exist and are of limited value. The
emergence of genetic testing has demonstrated that unique patient characteristics do influence
the effectiveness of opioids. Incomplete cross-tolerance may exist between different opioids
and care should be exercised when converting high doses of opioids. Particular care is
exercised with methadone and transdermal patches of fentanyl since a steady state is not
reached quickly with these drugs. Dose escalations should be made after several days of
treatment rather than changed on a daily basis. Patients are likely to retain previous prescrip‐
tions of opioids and may use old prescriptions of long acting opioid to supplement new
prescriptions. Some patients may need hospitalization for opioid management and drug
holidays, or formally detoxed.
17.2. Other drugs
Ketamine, buprenorphine, butorphanol and other classes of drugs may also be abused or
misused along with opioid agonists. Many of these drugs are not detected by routine drug
screening, and physicians should welcome information from the patients' family members or
friends about the patient's drug and alcohol use.
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18. Clinical vignette
A patient with mesothelioma repeatedly escalated their analgesic and called for early refills.
The doses exceeded recommended doses and the patient was repeatedly counseled. The
patient would not comply and the medication was discontinued. The medication was ketor‐
olac. The behavior was indistinguishable from opioid addiction. This patient eventually died
and was managed with other treatments but none were as effective as the intravenous NSAID
administered by the patient via a port.
Lesson learned-pseudo-addiction is a real condition and some patients are not able to cope
with pain and comply with treatment recommendations. NSAID and acetaminophen abuse
are significant problems.
18.1. Intrathecal opioid
Intrathecal opioid infusions have been used to limit oral opioid consumption and control
patients who self-escalate doses of opioids. There is little data to support the notion that spinal
opioids prevent addiction; however, in a randomized trial of intrathecal opioid versus oral
opioid for cancer pain management, patients treated with intrathecal opioid had a 6 month
survival rate of 52-59% compared to 32% in the oral opioid group. [81] This suggests that
intrathecal opioid may have a safety benefit related to controlled dosing.
18.2. Clinical vignette
A patient had an outpatient trial of intrathecal morphine but did not disclose that they were
seeing a psychiatrist who was prescribing benzodiazepines. The patient had a respiratory
arrest the morning after the injection.
Lesson learned-intrathecal opioid injections may not have a peak effect until the next day.
Patients may need to be hospitalized for trials with intrathecal opioids, especially morphine
or other opioids which may have a delayed peak effect.
The Wiley catheter may be used for intrathecal opioid trials and has been associated with a
lower incidence (3% versus 10% with larger catheters) of spinal headache in obstetrical
patients. [82]
Patients, who respond to a test dose of 0.5 mg of morphine or less, tend to maintain responses
to intrathecal opioid. Other factors of success include female gender, age over 65 and a
diagnosis of peripheral neuropathic pain. Patients with cervical pain and visceral pain tend to
require more rapid dose escalations. [83]
Patients, who respond only to higher doses during a trial, require more dose escalations,
conversations to alternative opioids, including oral opioids, and the addition of additional
agents such as bupivacaine. Lower daily doses of morphine, as a single agent, may be
associated with less risk for granuloma formation, which has been a significant problem with
long term intrathecal opioid therapy. Meperidine has been associated with pump malfunctions
and should be avoided.
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Popular opioid conversion ratios of 100:10:1 for intravenous to epidural to intrathecal may
vary significantly in clinical application, and conservative doses should be used to avoid
overdoses. Morphine concentrations of 20mg/ml and doses of 0.25mg/day are ideal.
19. Interventional pain management as an alternative to chronic opioid
therapy
Procedural interventions to treat pain are attractive options to avoid known and unknown
risks of chronic drug exposure. Frequently, interventions assist in diagnosis of the painful state
and reduce the opioid load. Also, the cost of some drug therapy is substantial and comparable
to procedures over time. Some patients report prolonged periods of pain improvement
following interventional procedures.
An example of a useful interventional procedure is epidural lysis of adhesions after years of
chronic low back and leg pain. Patients sometimes retain years of improved function and
quality of life after this procedure.
20. Interdisciplinary treatment as an alternative to chronic opioid therapy
Interdisciplinary pain management, as an alternative to continuing chronic opioid therapy,
has been offered to patients over the past year in our practice. The interdisciplinary program
included 8 half day sessions over a 4 week period. Each half day session included 1 hour of
cognitive behavioral therapy as a part of a structured sequence of sessions. Theories of pain,
relaxation techniques, cognitive restructuring, stress management, pacing, pleasant activity
scheduling, anger management, assertiveness training, sleep hygiene, and planning for flare-
ups included in the curriculum of care. Each half day session also includes 1 hour of psycho-
educational group therapy to complement the individual cognitive behavioral therapy. 1 hour
of physical therapy for general conditioning, specific range of motion and strengthening is also
an integral part of the program. Physician visits are scheduled during these half day sessions
for medication management and limited interventional pain management.
45 patients completed the interdisciplinary treatment program and were able to reduce or
eliminate opioids. At the same time, functional improvement was made across multiple
measures. Figure 1 shows average pain in previous week. Patients' median pain score dropped
approximately 35% after the interdisciplinary treatment.
Figure 2 shows a drop in median opioid dose from low to none. In this analysis, 1=no opioid,
2=low opioid dose (1-40mg per day of oral morphine equivalents), 3=moderate opioid dose
(40-100 mg per day of oral morphine equivalents), 4=high dose opioid (greater than 100 mg
per day of oral morphine equivalents).
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Figure 1. Visual analogue pain scores
Figure 2. Opioid doses
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Figure 3 shows a reduction in pain interference after interdisciplinary treatment.
Figure 3. Pain interference scores
A significant group of patients did not pursue interdisciplinary treatment and no outcome
data is available to compare with the patients who completed the program. However, the 45
patients who did reduce or eliminate opioids, their risk for overdose and diversion is probably
significantly lower and their function is clearly improved, along with functional existence.
Perhaps patients who chose not to participate in interdisciplinary care have pain that was
opioid responsive, and made the right decision. On the other hand, it is likely patients who
did not participate would have benefitted if they had chosen to participate.
In any event, patients do need alternatives to continued chronic opioid therapy and interdis‐
ciplinary treatment is a viable option for at least some of the large number of patients who
have been treated with opioids.
20.1. Tapering off
Many patients are prescribed opioid therapy by one doctor and then continue chronic opioid
therapy with another doctor. Once patients have been exposed to opioids for a prolonged
period of time, it becomes difficult to change the pain management approach and extinguish
opioid-liking behaviors. However, continuing chronic opioid therapy that was initiated by
another doctor is not addressed well in current guidelines. The single prescriber principle,
interpreted literally, would mean that "taking over" opioid prescribing from another doctor
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would be prohibited. The reality is that patients change insurance, move, and choose to change
doctors over the course of years for a number of valid reasons. Existing opioid therapy may
not be an indication for continuing chronic opioid therapy, and primary care physicians, as
well as specialists, need to be prepared to refer patients for detoxification if guidelines for
opioid therapy cannot be met due to a lack of a proper pain diagnosis or red flags for abuse
exist. Legitimate need is reassessed on a regular basis.
Patients may refuse detoxification as a means to continue opioid therapy. The prescribing
physician should be reluctant to allow a patient to "go cold turkey" and should have some skill
and understanding of tapering opioids. A gradual but firm reduction over a period of weeks
is adequate for most patients. Patients with addiction should be referred for addictionology
care and encouraged to receive expert help. Not all opioids can be tapered, such as Methadone,
without a special attachment to the DEA certificates. Physicians trained in addictionology are
best suited to treat patients who overlap pain and opioid dependence.
21. Clinical vignette
An elderly couple took different doses of hydrocodone from different doctors. They began
sharing medication. Both needed to be tapered off and they refused and were discharged.
Signed, written opioid agreements were in effect, which helped diffuse the situation.
Lesson learned-having opioid treatment agreements signed by the patient are helpful when
patients need to be tapered of opioid and/or discharged for a medical practice. Patients who
are terminated from a medical practice for cause should be sent a certified letter and followed
for 30 days while alternative care is arranged.
Patients may be tapered off opioid over a period of days to weeks. Rapid Benzodiazepine
withdrawal is associated with seizures and should proceed slowly in conjunction with
psychiatric care if accessible. Clonidine patch 0.1 mg/day may be helpful managing symptoms
of opioid withdrawal, as well as hydroxyzine as an anxiolytic.
22. REMS
Risk evaluation and mitigation strategies (REMS) training is required for long acting and
sustained release opioid prescribing. These measures are varied depending on the specific
opioid preparation. Standardization of REMS requirements will eventually assist to meet
guidelines [84].
22.1. Alternatives to chronic opioids
Tamper resistant preparations, buprenorphine, tramadol and new agents may help reduce the
diversion associated with chronic opioid therapy. Interdisciplinary evaluations including
interventional pain evaluations, psychological and physical therapy evaluations invariably
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lead to alternatives to chronic opioid therapy. Many chronic pain patients may be managed
without opioids, and adjunctive medications enhance sleep, diminish depression and anxiety
observed as comorbidities.
22.2. Guidelines
Multiple guidelines have been promulgated for opioid treatment of chronic pain. Experts in
the field have published guidelines but new information about the risks of opioids necessitates
new guidelines at this time. The American Society of Interventional Pain Physicians (ASIPP)
updates controlled substance guidelines every two years. This exhaustive effort is available
for download on the internet at www.asipp.org [85].
22.3. Labeling
In 2013, The Food and Drug Administration in the United States required new labeling
information for opioids that are long acting:
"TRADENAME is:
• A strong prescription pain medicine that contains an opioid (narcotic) that is used to manage
pain severe enough to require daily around-the-clock, long-term treatment with an opioid,
when other pain treatments such as non-opioid pain medicines or immediate-release opioid
medicines do not treat your pain well enough or you cannot tolerate them.
• A long-acting (extended-release) opioid pain medicine that can put you at risk for overdose
and death. Even if you take your dose correctly as prescribed you are at risk for opioid
addiction, abuse, and misuse that can lead to death.
• Not for use to treat pain that is not around-the-clock."
The use of long acting drugs for acute post-operative pain should be limited to special
circumstances such as opioid tolerance or burn pain.
Recently, the Federation of State Medical Boards issued a new model policy including the
following statement: "Additionally, providers should not continue opioid treatment unless the
patient has received a benefit, including demonstrated functional improvement." [86] Most
studies of opioids for chronic pain have shown incremental improvements in pain but have
failed to show functional improvement. Therefore, it seems as though chronic opioid therapy
is unlikely to continue as an accepted treatment for most patients.
Washington State has developed new workers' compensation guidelines in response to an
epidemic of overdoses. [87] These guidelines are an attempt to objectify treatment for subjec‐
tive symptoms. The guidelines restrict the use of chronic opioid therapy to very few special
cases. The guidelines reserve opioids for VAS >7 and limit the dose to 120mg/day of oral
morphine equivalents. The duration of treatment is limited to weeks. Continuation of opioids
must be associated with a 30% improvement on a 2-question instrument for pain and function.
Interestingly, the guidelines allow for marijuana use even though marijuana use has been
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associated with the use of more dangerous illicit substances. Restrictive guidelines such as
these are fraught with contradiction and the potential for limiting access to therapy.
New opioid prescribing guidelines with a "safe harbor" prescribing clause including doses and
duration of intervals between follow –up visits for reevaluation and prescription refills. Most
prescribing laws, rules and guidelines mandate a single prescriber and pharmacist yet a single
decision maker model is a major factor in making an individual physician vulnerable to
disciplinary action.
22.4. Clinical vignette
An elderly obese woman with intractable severe pain was bedridden and demanded more
opioid. Her bedridden status was confirmed and no additional opioid was prescribed. She
responded by saying "you want me to be in pain".
Lesson learned-in the current environment, increases in opioid doses need to be associated
with increased function.
22.5. Cancer pain
The use of opioids for cancer pain is excluded from restrictions in most guidelines. However,
many patients with cancer survive long-term and are really chronic pain patients. Cancer
treatment may produce chemotherapy related neuropathy, radiation plexopathy, and chronic
post-operative pain such as post mastectomy syndrome, post thoracotomy syndrome and
phantom pain syndrome. Pathologic fractures, especially vertebral body fractures, respond to
interventional procedures. Interventional options for vertebral fractures include vertebroplas‐
ty, facet injections, and lysis of adhesions, quadratus lumborum or psoas injections, or
transforaminal catheter techniques for chronic pain.
Neuromodulation may be useful in patients with neuropathic pain resulting from successful
cancer treatment. Patients need to be evaluated for myofascial pain, radiculopathy and other
common pain syndromes with careful history taking and physical examination. Terminally ill
patients do have options for treatment other than escalating opioid doses. Trigger point
injections, lysis of adhesions and other interventional therapies are often very helpful man‐
aging patients with cancer who may or may not ultimately die from neoplasia.
CLINICAL VIGNETTE patient with pain in the groin, scrotum and sacral area following
radiation left the patient unable to sleep in any position other than in a chair in a knees-to-
chest position. The patient responded to sacral electrode stimulation bilaterally at S3. A year
later, the patient had more pain and responded to stimulation at S2.
Lesson learned-Following aggressive cancer treatment, there are devastating pain conditions
that are not terminal but do respond to interventional techniques but not to opioids.
Cancers of  the cervix,  rectum and other tissues produce pelvic pain syndromes that are
often difficult  to treat.  Patients who have undergone abdominal-perineal resections have
pain syndromes that may not respond well to opioids. This group of patients may have
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pain  with  sitting  and  tenderness  to  palpation  over  the  ischial  tuberosity  (Racz's  sign).
Ricardo Plancarte describes the inferior hypogastric block may provide significant relief in
some of these patients. [88]
A unilateral inferior hypogastric block is the preferred procedure for patients with unilateral
pain and ischial tenderness. The inferior hypogastric plexus is more anatomically defined
compared to the superior hypogastric plexus,  which is  more diffuse.  A diagnostic block
should be performed, preferably with a curved blunt needle, before a neurolytic block with
phenol 6%, 4-5 ml. [89] Erdine reported a transdiscal approach that may be the most effective
technique. [90]
"Morphinemia" (a lack of morphine) should not be considered as the primary problem in every
patient with cancer related pain. Opioids are prescribed for patients who respond to them, but
additional options are explored in order to respond to a patient in need of pain relief, who
does not respond adequately to increasing doses of opioids.
Methylnaltrexone for opioid related constipation in palliative care patients may be used
when laxatives and other measures are inadequate. Constipation can cause abdominal pain
and treating this with more opioid continues the cycle.  The dose of methylnaltrexone is
0.15 mg/kg.
Opioids also control rest pain, but not movement related pain. Opioids do reduce the likeli‐
hood of a patient becoming bedridden. Metastases usually do not invade vertebral pedicles
early, and patients respond to lysis of adhesions enough to be able to walk. [91,92]
Clinical vignette-a patient with spinal metastasis responded for 3 months to lysis of adhesions.
The patient became bedridden again and responded to a second procedure.
Lesson learned-some patients with terminal cancer may have improved quality of life with
interventional techniques that otherwise would not be produced with opioids alone.
Patients with upper abdominal cancer pain may benefit  from splanchnic radiofrequency
ablation. Quality of life and pain control have been improved in studies using this technique. [93]
Patients with cancer related pain should be evaluated for interventional procedures that may
improve their quality of life and suffering. Patients with terminal illness may become isolated
from medical specialists and be treated by mid-level practitioners who are unfamiliar with
options other than opioid escalation. Cancer pain treatment requires a team approach to afford
optimal care.
Other conditions beyond cancer are legitimate palliative diagnosis for opioid use. Patients
with  end  stage  coronary  artery  disease  and  congestive  heart  failure  are  treated  with
morphine, not for chest pain, but for the venous dilatory effect, decrease cardiac preload,
and reduction in shortness of breath. Patients who are bedridden with osteoporotic fractures
are  another  example of  patients  with chronic  pain at  the end of  life,  and opioids  are  a
compassionate treatment companion. Every drug used for pain has toxicity and side effects
that  sometimes  precludes  its  use.  Sometimes  opioids  are  the  least  toxic  option  in  the
palliative care setting.
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23. Conclusions
Patients who request relatively small doses of opioids for conditions such as arthritis pain often
do well over a period of years. This experience reinforces a practitioner's belief in the efficacy
of chronic opioid therapy. However, addictionologists and pain specialists often witness a very
different side of pain treated with opioids.
The prescribing clinician strives to improve the ability to identify patients who will do poorly
with opioids, but we also strive to identify patients who will do well with this option. Gener‐
ally, lower doses, less potent drugs, and shorter durations of therapy are associated with
improved outcome and reduced adverse events. Some have suggested that opioids are to be
used intermittently, not on a daily basis, for "breakthrough pain" only, along with other drug
classes for "basal" analgesia. Others believe long-acting pharmacokinetically smooth agents
are best suited for chronic pain.
The public health problem of overdose deaths has overridden the notion that the individual
patient and their physician are free to use opioids for chronic pain without fear of legal and
regulatory action and physicians need to anticipate the substantial shift in policy of regulators
who authorize the privilege of practicing medicine.
Physicians are encouraged to err on the side of less opioid, rather than more opioid, and
improve their skills in providing patient satisfaction with other drugs for chronic pain known
as adjuncts. Non-drug treatments for pain need to be maximized as well prior to initiating
opioid therapy. Tramadol and low dose potent opioids with defined frequent follow-up visits
for refills are a necessary part of the practice of standard care despite the lack of long term
randomized controlled trials.
Although contradictory to the patient/physician relationship, physicians must improve their
ability to say “no” to the patient who demands opioids. This is weighed against alienating
patients who have legitimate pain, but co-morbidities that place them at risk for bad outcomes
from chronic opioid therapy. [94] Pain research, public education, patient education and
medical education need to improve so that pain can be treated more successfully and safely.
Improved diagnosis and treatment should lead to more cost effective treatment.
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